Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide^[@R1]^. Cetuximab and panitumumab are EGF receptor (EGFR) monoclonal antibodies (mAbs) that bind the extracellular domain of EGFR and enhance receptor internalization and degradation. These EGFR mAbs are common targeted agents for patients with wild-type *KRAS* metastatic CRC. As monotherapy, 12--17% patients have durable responses^[@R2]^ and up to 72% response rates are reported when combined with chemotherapy^[@R3]^. However, drug resistance frequently arises. Intense efforts have led to identification of many *de novo* and acquired genetic mechanisms of resistance to EGFR mAb therapy, including *KRAS*, *NRAS*, *BRAF*, *PIK3CA*, and *EGFR* mutations^[@R2],[@R4],[@R5]^. However, little is known about non-genetic resistance mechanisms.

Non-coding RNAs (ncRNAs), in particular long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), play crucial roles in epigenetic regulation^[@R6],[@R7]^. Recently, a complex interplay between these two classes of regulatory ncRNAs has been discovered in which some lncRNAs are processed to produce miRNAs that repress target mRNAs^[@R8],[@R9]^. For example, lncRNA H19-derived miR-675 suppresses translation of insulin growth factor receptor (Igf1r), inhibiting cell proliferation in response to cellular stress or oncogenic signals^[@R10]^. miR-17∼92, generated from the lncRNA MIR17HG locus, attenuates TGF-β signaling to stimulate angiogenesis and tumor growth^[@R11]^. The lncRNA MIR100HG-derived miR-100/let-7a-2/miR-125b-1 and MIR99AHG-derived miR-99a/let-7c/miR-125b-2 clusters participate in the pathogenesis of acute megakaryoblastic leukemia^[@R12],[@R13]^. However, whether these lncRNAs or derived miRNAs contribute to drug resistance is largely unknown.

Herein, we identify a role for lncRNA MIR100HG and two embedded miRNAs, miR-100 and miR-125b, in conferring cetuximab resistance. We show that MIR100HG and miR-100/125b are overexpressed in the setting of *de novo* and acquired cetuximab resistance in CRC and head and neck squamous cell cancer (HNSCC) cell lines. miR-100 and miR-125b coordinately downregulate five negative regulators (DKK1, DKK3, ZNRF3, RNF43, APC2) of canonical Wnt/β-catenin signaling (hereafter Wnt signaling), leading to increased Wnt signaling. Wnt inhibition restores responsiveness to cetuximab *in vitro* and *in vivo*. We show these events occur in CRC patients whose tumors progressed on cetuximab. We also discovered that MIR100HG overexpression is reinforced by miR-125b suppression of GATA6, which in turn represses MIR100HG. These studies identify an epigenetic cause of cetuximab resistance with diagnostic and therapeutic implications.

Results {#S1}
=======

Establishment of cetuximab-resistant cells in three-dimensional (3D) culture {#S2}
----------------------------------------------------------------------------

By placing single cells from a human *KRAS/NRAS/BRAF* wild-type, microsatellite unstable CRC cell line, HCA-7, into 3D culture in type-1 collagen, a line was derived from colonies with cystic morphology and designated cystic colonies (CC) ^[@R14],[@R15]^. Proliferation of CC was inhibited by cetuximab in 3D culture but not in 2D plastic culture^[@R14]^. Upon continuous exposure to cetuximab in 3D culture for approximately 4 months, a line was generated and designated CC-cetuximab resistant (CC-CR) ([Fig. 1a](#F12){ref-type="fig"}). In 2D culture, CC and CC-CR were morphologically indistinguishable. In 3D, however, CC formed hollow cysts with a central lumen lined by a monolayer of polarized cells, whereas CC-CR formed solid disorganized colonies ([Fig. 1b](#F12){ref-type="fig"}). As expected, cetuximab inhibited CC growth in 3D, while CC-CR remained refractory to cetuximab up to 200 μg/ml ([Fig. 1c](#F12){ref-type="fig"}; [Extended Data Fig. 1a and b](#F1){ref-type="fig"}). Decreased expression of the proliferative marker, Ki-67, and increased expression of the apoptotic marker, cleaved Caspase-3, were observed in CC 24 h after cetuximab treatment, but these indices were unaffected in CC-CR ([Fig. 1d](#F12){ref-type="fig"}). In cetuximab-treated CC, we observed reduced levels of p-EGFR, p-ERK1/2, p-AKT and Cyclin D1, as well as increased cleaved Caspase-3 and the pro-apoptotic marker, BIM; these markers were largely unaffected in cetuximab-treated CC-CR ([Fig. 1e](#F12){ref-type="fig"}). Next, CC and CC-CR were stably transduced with a green fluorescent protein (GFP)-expressing lentiviral vector and injected subcutaneously into athymic nude mice. CC tumors were well differentiated and regressed upon administration of cetuximab. In contrast, CC-CR tumors were poorly differentiated and continued to grow in the presence of cetuximab, although not to the extent of untreated tumors ([Fig. 1f and g](#F12){ref-type="fig"}; [Extended Data Fig. 1c-e](#F1){ref-type="fig"}).

Upregulation of lncRNA MIR100HG and embedded miR-100/125b in cetuximab-resistant cells {#S3}
--------------------------------------------------------------------------------------

We first considered known mechanisms of cetuximab resistance in this 3D model. By whole exome sequencing and RNA Sequencing (RNA-Seq), no known genetic events linked to cetuximab resistance were found, including all reported gene mutations, copy number changes and gene fusion events ([Extended Data Table 1](#T1){ref-type="table"}). By RNA-Seq, we found 141 transcripts upregulated and 220 transcripts downregulated in CC-CR compared to CC (fold change\>2 and false-discovery rate, FDR\<0.01). Expression levels of ERBB1-4, the 7 EGFR ligands, and MET were comparable between CC and CC-CR ([Extended Data Table 2](#T2){ref-type="table"}). Immunofluorescence also showed equivalent cell-surface EGFR staining in CC and CC-CR ([Extended Data Fig. 1f](#F1){ref-type="fig"}). Small RNA-Seq detected 7 miRNAs upregulated and 24 miRNAs downregulated in CC-CR compared to CC (fold change\>2 and FDR\<0.01). Of note, the most upregulated transcript in CC-CR was lncRNA MIR100HG, and the two most upregulated miRNAs were miR-125b and miR-100 ([Fig. 2a](#F13){ref-type="fig"}).

MIR100HG is the host gene of the miR-100/let-7a-2/miR-125b-1 cluster on chromosome 11 ([Fig. 2b](#F13){ref-type="fig"}). qRT-PCR analysis confirmed upregulation of endogenous MIR100HG expression in CC-CR in the presence or absence of cetuximab ([Fig. 2c](#F13){ref-type="fig"}). pri-miR-100, pri-miR-125b-1, and their corresponding mature miRNA, miR-100 and miR-125b, were also enriched in CC-CR ([Fig. 2c](#F13){ref-type="fig"} and [Extended Data Fig. 2a](#F2){ref-type="fig"}). Although pri-let-7a-2 was upregulated in CC-CR, mature let-7a was unchanged compared to CC ([Extended Data Fig. 2b](#F2){ref-type="fig"}). The transcriptional start site (TSS) of MIR100HG was confirmed by 5′ RACE-PCR ([Extended Data Fig. 2c](#F2){ref-type="fig"}). Analysis of The Cancer Genome Atlas (TCGA) CRC data repository revealed that miR-100 and miR-125b expression is tightly correlated with MIR100HG expression ([Fig. 2d](#F13){ref-type="fig"}). RNA fluorescence *in situ* hybridization (FISH) showed highly enriched MIR100HG and miR-100/125b expression in CC-CR tumor xenografts ([Fig. 2e](#F13){ref-type="fig"}). In contrast, let-7a expression did not correlate with that of MIR100HG ([Extended Data Fig. 2d](#F2){ref-type="fig"}).

To assess whether MIR100HG and miR-100/125b overexpression extended beyond this one cell line, we examined their expression in a panel of 30 CRC cell lines placed upon a continuum of cetuximab sensitivity and resistance based upon published reports^[@R16],[@R17]^ ([Extended Data Table 3](#T3){ref-type="table"}). Expression of MIR100HG and miR-100/125b were enriched in more cetuximab-resistant lines compared to the more sensitive lines ([Fig. 2f](#F13){ref-type="fig"}). Their expression inversely correlated with cetuximab resistance, regardless of *KRAS*/*BRAF* mutational status ([Extended Data Fig. 2e and f](#F2){ref-type="fig"}). For example, two of the cetuximab-sensitive lines (GEO and SW403) expressed low levels of MIR100HG and miR-100/125b despite harboring mutant *KRAS.* In addition, we also observed upregulation of MIR100HG and miR-100/125b in the setting of cetuximab resistance in HNSCC cell lines ([Extended Data Fig. 3a](#F3){ref-type="fig"}). Thus, MIR100HG and miR-100/125b are upregulated in the setting of cetuximab resistance in CRC and HNSCC cell lines and this phenomenon occurs in both acquired and *de novo* resistance. These findings led us to further explore the function of MIR100HG and miR-100/125b in cetuximab resistance.

miR-100 and miR-125b cooperativity drives cetuximab resistance {#S4}
--------------------------------------------------------------

Since a major role of certain lncRNAs is production of embedded miRNAs^[@R10],[@R18]^, we asked whether cetuximab resistance is mediated by miR-100 and miR-125b overexpression. To this end, we delivered lentiviral-based overexpression or sponge constructs into CC and CC-CR, respectively, to generate stable cell lines expressing each miRNA, the miR-100/125b bicistron, or their corresponding sponges ([Extended Data Fig. 3b and c](#F3){ref-type="fig"}). Although the miR-100 sponge had no significant effect on colony number in CC-CR in 3D culture, both the miR-125b and bicistron sponges significantly reduced colony number ([Fig. 3a](#F14){ref-type="fig"}). In the presence of cetuximab, the miR-100 sponge modestly reduced colony number, whereas the reduction in colony number was more pronounced with the miR-125b sponge and the bicistron sponge ([Fig. 3a](#F14){ref-type="fig"}). In contrast, opposite effects were observed in CC upon overexpressing miR-100 and miR-125b individually and together. The miR-100/125b bicistron, but not individual miRNAs, increased colony number in CC ([Fig. 3b](#F14){ref-type="fig"}). Upon cetuximab treatment, the miR-100/125b bicistron conferred the strongest pro-survival effect; when introduced individually, miR-125b had a greater effect than miR-100 ([Fig. 3b](#F14){ref-type="fig"}). Similar opposing effects were observed in morphological changes, as well as Ki-67 and cleaved Caspase-3 staining upon expressing the different sponges in CC-CR and the different miRNAs in CC ([Fig. 3c and d](#F14){ref-type="fig"}; [Extended Data Fig. 3d and e](#F3){ref-type="fig"}). Additionally, overexpression of the miR-100/125b bicistron in Caco-2 cells (low endogenous miR-100/125b expression) rendered cells less responsive to cetuximab, whereas inhibition of the miR-100/125b bicistron in DLD-1 cells and HNSCC SCC25-derived CTX-R7 cells (both with high endogenous miR-100/125b expression) restored cetuximab responsiveness ([Extended Data Fig. 4](#F4){ref-type="fig"}). Similar results were observed when CC-CR and CC cells with the differing manipulations were established as subcutaneous xenografts in nude mice and treated with cetuximab ([Fig. 3e and f](#F14){ref-type="fig"}; [Extended Data Fig. 5](#F5){ref-type="fig"}). Together, these results are consistent with a model in which miR-100 and miR-125b cooperate to confer cetuximab resistance.

miR-100 and miR-125b repress multiple Wnt negative regulators and increase Wnt signaling {#S5}
----------------------------------------------------------------------------------------

To understand how miR-100 and miR-125b influence cetuximab responsiveness, we considered the most downregulated genes in CC-CR to be potential targets of these miRNAs. Two negative regulators of Wnt signaling, DKK1 and DKK3, were decreased over 30-fold in CC-CR compared to CC ([Fig. 2a](#F13){ref-type="fig"}). Meanwhile, Wnt activity was enhanced in CC-CR by analysis of 64 consensus β-catenin target genes^[@R19]^ ([Extended Data Fig. 6a](#F6){ref-type="fig"}). Analysis of a large human CRC dataset (n=458) also revealed that MIR100HG expression levels positively correlated with the Wnt score^[@R19]^, whereas no correlation was observed between MIR100HG and the Ras-Az score^[@R20]^, which measures MEK activation as a downstream index of RAS signaling ([Extended Data Fig. 6a](#F6){ref-type="fig"} and data not shown). Functional enrichment analysis further identified Wnt pathway enrichment in miR-100 and miR-125b putative targets ([Extended Data Table 4](#T4){ref-type="table"}). We thus considered whether miR-100 and miR-125b might target components of Wnt signaling. Through computational target prediction, we found that 3′ UTRs of DKK1 and DKK3 contain binding sites for miR-100 and miR-125b, respectively ([Fig. 4a](#F15){ref-type="fig"}). Since clustered miRNAs are co-expressed and often coordinately regulate molecular pathways by targeting different components of the same pathway^[@R21]^, we searched for other negative regulators of Wnt signaling that contain putative binding sites for miR-100 or miR-125b, and identified zinc and ring finger 3 (ZNRF3), ring finger protein 43 (RNF43), and APC2 as potential targets of miR-100 or miR-125b alone or in combination ([Fig. 4a](#F15){ref-type="fig"} and [Extended Data Table 5](#T5){ref-type="table"}). Decreased protein levels of these five Wnt negative regulators in CC-CR compared to CC were confirmed by both immunoblots in cell lines and immunostaining in xenografts ([Extended Data Fig. 6b and c](#F6){ref-type="fig"}). Using 3′ UTR luciferase reporter assays, we confirmed these five candidates are direct targets of miR-100 and/or miR-125b in both CC and Caco-2 cells; repression of these genes was rescued by mutations in the corresponding binding sites ([Fig. 4b and c](#F15){ref-type="fig"}; [Extended Data Fig. 6d](#F6){ref-type="fig"}). Immunoblots confirmed the regulation of the predicted targets by miR-100 and miR-125b alone or in combination in CC and CC-CR ([Fig. 4d](#F15){ref-type="fig"}). Consistently, this regulation was also observed in Caco-2 cells (low endogenous miR-100/125b expression) and HuTu80 cells (high endogenous miR-100/125b expression) ([Extended Data Fig. 6e](#F6){ref-type="fig"}).

We next examined whether miR-100/125b-induced downregulation of these Wnt negative regulators resulted in increased Wnt signaling. Although total β-catenin levels were not significantly altered, CC-CR exhibited increased active tyrosine phosphorylated p-Y489 β-catenin and increased nuclear β-catenin compared to CC in 3D ([Fig. 4e](#F15){ref-type="fig"} and [Extended Data Fig. 6f](#F6){ref-type="fig"}). Consistently, β-catenin was largely confined to the plasma membrane in CC xenografts, whereas it was largely nuclear in CC-CR xenografts ([Fig. 4f](#F15){ref-type="fig"}). Moreover, mRNA expression of a panel of Wnt target genes was significantly enriched in CC-CR versus CC ([Fig. 4g](#F15){ref-type="fig"}). Cetuximab blocked Wnt3a-induced Wnt activation in CC, but had no obvious effect on Wnt3a-induced Wnt signaling in CC-CR ([Extended Data Fig. 6g](#F6){ref-type="fig"}). Cetuximab also led to a marked and persistent decrease in Wnt target genes in CC over 48 h, whereas expression of those genes in CC-CR was only modestly decreased at early time points after treatment before rebounding at later time points ([Extended Data Fig. 6h](#F6){ref-type="fig"}). Furthermore, nuclear β-catenin levels increased in CC and Caco-2 cells stably overexpressing either miR-100 or miR-125b, and the increase was greater in cells expressing the miR-100/125b bicistron ([Extended Data Fig. 7a](#F7){ref-type="fig"}). In contrast, nuclear β-catenin levels were reduced upon overexpressing the miR-100/125b bicistron sponge in CC-CR, DLD-1, and CTX-R7 cells ([Extended Data Fig. 7a](#F7){ref-type="fig"}). Corresponding changes of Wnt target genes were also observed ([Fig. 4h](#F15){ref-type="fig"} and [Extended Data Fig. 4e](#F4){ref-type="fig"}). Consistent with these findings, nuclear β-catenin immunoreactivity increased in CC nude mouse xenografts expressing the miR-100/125b bicistron and decreased in their CC-CR counterparts expressing the bicistronic sponge ([Extended Data Fig. 7b](#F7){ref-type="fig"}).

Based on our findings that Wnt signaling is increased in CC-CR, we hypothesized that cetuximab responsiveness may be restored by suppression of Wnt signaling. Since DKK1 and DKK3 are secreted Wnt antagonists and among the most downregulated genes in CC-CR, we tested whether their overexpression could overcome cetuximab resistance using a doxycycline-inducible lentiviral system^[@R22]^. Although induction of DKK1 or DKK3 resulted in a slight reduction in colony number, this effect was augmented with addition of cetuximab ([Extended Data Fig. 8a and b](#F8){ref-type="fig"}). Moreover, administration of recombinant DKK1 and DKK3 enhanced the ability of cetuximab to decrease proliferation and increase apoptosis ([Extended Data Fig. 8c](#F8){ref-type="fig"}). Furthermore, nuclear β-catenin expression decreased when DKK1 or DKK3 was inducibly expressed in CC-CR in the presence of cetuximab ([Extended Data Fig. 8d](#F8){ref-type="fig"}). We next tested whether pharmacological inhibition of Wnt activity sensitized CC-CR to cetuximab using a tankyrase inhibitor, XAV-939^[@R23]^, and a β-catenin/CBP inhibitor, ICG-001^[@R24]^. Both compounds caused a concentration-dependent reduction in colony number, and cetuximab growth inhibition was enhanced by their addition ([Extended Data Fig. 8e](#F8){ref-type="fig"}). ICG-001 also enhanced the growth inhibitory effects of cetuximab in other CRC and HNSCC cell lines with high expression of MIR100HG ([Extended Data Fig. 8f](#F8){ref-type="fig"} and [4e](#F15){ref-type="fig"}). In CC-CR nude mouse xenografts, administration of cetuximab and ICG-001 individually only slowed tumor growth; however, combined treatment resulted in tumor regression ([Fig. 4i-k](#F15){ref-type="fig"}; [Extended Data Fig. 8g and h](#F8){ref-type="fig"}). Thus, blockade of Wnt signaling, either upstream or downstream of the APC/β-catenin degradation complex, restores cetuximab responsiveness to cetuximab-resistant cells.

Reciprocal negative regulation between GATA6 and MIR100HG/miR-125b {#S6}
------------------------------------------------------------------

To explore mechanism(s) by which miR-100 and miR-125b are upregulated in CC-CR, we investigated transcriptional regulation of the host gene, MIR100HG. Possible transcription factors containing binding sites within the 2.5 kb promoter of MIR100HG were mapped *in silico* using the Match program (version 1.0)^[@R25]^ and cross-referenced with the RNA-Seq dataset ([Extended Data Table 6](#T6){ref-type="table"}). Among these transcription factors, we focused on the zinc-finger transcription factor GATA6, which was downregulated at both the mRNA and protein level in CC-CR in 3D culture and in nude mouse xenografts ([Fig. 2a](#F13){ref-type="fig"} and [Fig. 5a-c](#F16){ref-type="fig"}).

GATA6 is critical for gut endoderm development, and it both promotes and suppresses gastrointestinal and pancreatic neoplasia^[@R26]-[@R29]^. We found that MIR100HG expression decreased in cetuximab-treated CC, while GATA6 mRNA progressively increased over 48 h ([Fig. 5d](#F16){ref-type="fig"}); however, this phenomenon did not occur in CC-CR (data not shown). GATA6 knockdown in CC ([Extended Data Fig. 9a](#F9){ref-type="fig"} and [Fig. 5e](#F16){ref-type="fig"}, top) caused MIR100HG upregulation and its expression no longer decreased upon cetuximab treatment ([Fig. 5e](#F16){ref-type="fig"}, bottom), suggesting a repressive effect of GATA6 on MIR100HG. Luciferase reporter assays showed overexpression of GATA6 ([Extended Data Fig. 9b](#F9){ref-type="fig"}) resulted in a concentration-dependent inhibition of MIR100HG promoter activity ([Fig. 5f](#F16){ref-type="fig"}). Four putative GATA binding sites (G/A)GATA(A/T) were identified in the MIR100HG promoter region ([Fig. 5g](#F16){ref-type="fig"}). Sequential deletions and mutations of these binding sites revealed that GATA binding site 2 (-1198 upstream of the TSS) is the major site for GATA6 repression of MIR100HG transcriptional activity ([Fig. 5h](#F16){ref-type="fig"}). GATA6 repression of MIR100HG was also validated in HuTu80 cells with low expression of GATA6 and high expression of MIR100HG ([Extended Data Fig. 9c and d](#F9){ref-type="fig"}). Chromatin occupancy of GATA6 at GATA-binding site 2 was confirmed by chromatin immunoprecipitation (ChIP) and electromobility shift assay (EMSA) using nuclear extracts from CC cells ([Extended Data Fig. 9e and f](#F9){ref-type="fig"}).

Of interest, we found that the 3′ UTR of GATA6 harbors a putative binding site for miR-125b ([Extended Data Table 5](#T5){ref-type="table"}). In both CC and Caco-2 cells, introduction of miR-125b reduced luciferase activity of the wild-type 3′ UTR reporter construct, but not when the miR-125b site was mutated ([Fig. 5i](#F16){ref-type="fig"} and [Extended Data Fig. 9g](#F9){ref-type="fig"}). As predicted, GATA6 levels were reduced in CC and Caco-2 cells stably expressing miR-125b, and conversely increased in CC-CR and HuTu80 cells expressing the miR-125b sponge ([Fig. 5j](#F16){ref-type="fig"} and [Extended Data Fig. 9h](#F9){ref-type="fig"}). Further analysis of the TCGA data repository indicated that GATA6 is significantly downregulated, whereas MIR100HG is significantly upregulated in stage IV CRC patients ([Fig. 5k](#F16){ref-type="fig"}). Also, CRCs with lower quartile expression of GATA6 tend to have higher expression of MIR100HG in the TCGA data repository ([Fig. 5k](#F16){ref-type="fig"}), as well as in two additional CRC datasets ([Extended Data Fig. 9i](#F9){ref-type="fig"}). Together, these findings suggest a double-negative regulatory circuit between GATA6 and MIR100HG/miR-125b underlies cetuximab resistance.

Increased MIR100HG, miR-100, and miR-125b are found in CRC specimens at time of progression on cetuximab {#S7}
--------------------------------------------------------------------------------------------------------

To examine whether this mode of cetuximab resistance occurs in human CRC, we obtained paired tumor specimens from ten individuals prior to the start of cetuximab treatment and at the time of tumor progression ([Extended Data Table 7](#T7){ref-type="table"}). *KRAS/NRAS/BRAF* mutations had been excluded in tumor specimens obtained prior to treatment with cetuximab. qRT-PCR showed that miR-100 and miR-125b were coordinately overexpressed (*r*~s~=0.842, *P*\<0.01) in tumors that progressed on treatment compared to pre-treatment levels (*P*\<0.05, [Fig. 6a](#F17){ref-type="fig"}). In addition, nuclear β-catenin immunoreactivity was significantly higher in tumors that progressed on cetuximab ([Fig. 6b](#F17){ref-type="fig"}). miR-125b expression directly correlated with nuclear β-catenin staining (*r~s~*=0.636, *P*\<0.05); the correlation between miR-100 expression and nuclear β-catenin staining did not reach statistical significance (*r~s~*=0.612, *P*=0.06). Conversely and consistent with our pre-clinical findings, there was reduced nuclear GATA6 expression in tumors that advanced on cetuximab ([Fig. 6c](#F17){ref-type="fig"}). However, we did not find a significant inverse correlation between miR-100 and GATA6 (*r~s~*=-0.455, *P*=0.187), or miR-125b and GATA6 (*r~s~*=-0.515, *P*=0.128). By FISH analysis, the MIR100HG, miR-100, and miR-125b signals increased in tumors that progressed on treatment. In these same samples, there was increased β-catenin staining and reduced GATA6 staining ([Fig. 6d](#F17){ref-type="fig"}). We excluded *MET* amplification by FISH in all ten paired specimens and sequenced the post-treatment tumors for mutations in *KRAS/NRAS/BRAF* ([Extended Data Fig. 9j](#F9){ref-type="fig"} and [Extended Data Table 8](#T8){ref-type="table"}). *NRAS* and *KRAS* mutations were detected in 2 cases, respectively; we confirmed that these were likely acquired events by re-sequencing the pre-treatment DNA. In both cases, MIR100HG and miR-100/125b were increased. In the remaining 8 cases that lacked genetic resistance events, 5 cases exhibited upregulated MIR100HG and miR-100/125b in the tumors post-treatment. These clinical data support our pre-clinical findings and demonstrate that upregulation of MIR100HG and miR-100/125b occur in the setting of acquired cetuximab resistance in CRC patients, and this upregulation may both coincide with and be independent of genetic mutations associated with cetuximab resistance.

Discussion {#S8}
==========

MIR100HG is a polycistronic miRNA host gene, which encodes miR-100, let-7a-2, and miR-125b-1 within its third intron. MIR100HG was first reported to participate in fate determination of human mesenchymal stem cells^[@R30]^, and later found to be highly expressed in acute megakaryoblastic leukemia^[@R12],[@R13]^. Increased MIR100HG expression is associated with a poor prognosis in cervical cancer^[@R31]^, whereas its expression is reduced in breast cancer due to hypermethylation^[@R32]^. Increased expression of miR-100 and miR-125b are also correlated with gastric cancer progression in clinical samples^[@R33]^. In our study, concomitant upregulation of MIR100HG and miR-100/125b occurs in the setting of acquired and *de novo* cetuximab resistance in CRC and HNSCC cell lines. Moreover, we show these events can co-occur with *KRAS*/*NRAS/BRAF* mutation and in tumors of CRC patients that progressed on cetuximab. Analysis of TCGA CRC data repository revealed a stage-dependent increase of MIR100HG expression. These data support the hypothesis that MIR100HG and miR-100/125b are potential predictive biomarkers for cetuximab resistance.

We identified that miR-100 and miR-125b coordinately contribute to cetuximab resistance by targeting five negative regulators of Wnt signaling. miR-100 targets DKK1 and ZNRF3; miR-125b also targets ZNRF3, as well as RNF43, DKK3, and APC2. Wnt signaling is tightly regulated and negative regulators act at many different levels^[@R34],[@R35]^. DKK1 and DKK3 are secreted Wnt signaling antagonists of the Dickkopf family. DKK1 acts by binding and internalizing the Wnt co-receptor LRP5/6^[@R36]^, while it is unclear how DKK3 attenuates Wnt signaling^[@R37]^. ZNRF3 and RNF43 are two closely related transmembrane E3 ubiquitin ligases that antagonize Wnt signaling through ubiquitylation and degradation of the Wnt receptor Frizzled and its co-receptor LRP5/6^[@R38],[@R39]^. Although inactivating mutations have been reported for *ZNRF3/RNF43*^[@R40]^, our data suggest that downregulation by miR-100/125b may represent an alternative mechanism of attenuating ZNRF3/RNF43 function. APC2 targets β-catenin for destruction and is functionally complementary to APC^[@R41]^; it was recently reported that APC2 recruits TNKS into the β-catenin destruction complex to regulate β-catenin proteolysis^[@R42]^. We previously identified APC as a target of miR-125b in leukemia cells^[@R12]^, but did not examine APC in CC or CC-CR since it is mutated in these cells. However, it was recently reported that miR-125b targets APC in mutant β-catenin HCT116 cells that have wild-type *APC*^[@R43]^. The present study shows that miR-100 and miR-125b work together to target these five Wnt negative regulators, providing a novel regulatory mode for clustered miRNAs to cooperatively regulate this pathway.

We cannot exclude that miR-100/125b contributes to cetuximab resistance through means other than Wnt signaling. For example, miR-125b can enhance tumor formation in the skin by targeting vacuolar protein-sorting 4 homolog B (Vps4b) and indirectly prolonging EGFR activity^[@R44]^. However, we observed no differences in VPS4b expression between CC and CC-CR. We also have not excluded an effect of the full-length 3 kb MIR100HG transcript on Wnt signaling.

The present study adds to the literature describing crosstalk between EGFR and Wnt signaling^[@R45],[@R46]^. For example, in *APC-mutant* CRC, increased EGFR signaling enhances Wnt activity, supporting the notion that Wnt signaling is further modulated in the setting of an impaired β-catenin degradation complex^[@R47]^. In a reciprocal manner, binding of Wnt ligands to their GPCR Frizzled receptors results in EGFR transactivation via metalloprotease-dependent, cell-surface ectodomain cleavage of EGFR ligands^[@R48]^. Moreover, increased Wnt signaling confers resistance to EGFR tyrosine kinase inhibitors in lung cancer^[@R49],[@R50]^.

The precise mechanism by which increased Wnt signaling confers cetuximab resistance is uncertain. It has been reported that Wnt signaling increases EGFR expression in liver^[@R51]^. We observed that cetuximab did not reduce p-EGFR, pERK1/2, or p-AKT in CC-CR as it does in CC. Although there is equivalent cell-surface EGFR staining in CC and CC-CR, this does not exclude differences in rates of EGFR internalization, recycling and degradation. Going forward, a system-wide approach should prove useful to help unravel mechanisms underlying the EGFR/Wnt crosstalk in this system.

The role of GATA6 in cancer is complex and context-dependent; even in the same tumor type, conflicting evidence exists. For example, GATA6 promotes pancreatic carcinogenesis by activating Wnt signaling^[@R52]^. In separate studies, it serves a tumor suppressive role by maintaining a pancreatic differentiation program^[@R53],[@R54]^. Likewise, in colonic neoplasia, opposing actions are reported. In colonic adenomas, GATA6 represses BMP expression, thereby enabling stem cell self-renewal^[@R27]^, and in CRC cell lines, it enhances expression of Lgr5 and REG4 to promote clonogenicity and growth, respectively^[@R55],[@R56]^. In contrast, our study supports a tumor-suppressive role for GATA6 in CRC. Analysis of the TCGA CRC repository reveals reduction in GATA6 expression in stage IV CRC along with increased MIR100HG expression. Reduced expression of GATA6 would permit increased expression of MIR100HG, and the corresponding increased expression of miR-125b would reinforce repression of GATA6. In this context, GATA6 serves a permissive tumor suppressive role by preventing Wnt signaling-enhanced cetuximab resistance.

The present study has important therapeutic implications for CRC and HNSCC. It is increasingly appreciated that there are gradients of Wnt signaling in CRC^[@R57]^ and that Wnt signaling can be modulated in the setting of APC loss-of-function^[@R58],[@R59]^. In our model, MIR100HG- and miR-100/125b-mediated Wnt activation represents an adaption of activating compensatory pathways for cells to survive under EGFR inhibition. We show induction of DKK1 or DKK3 individually, or the combined addition of recombinant DKK1 and DKK3, overcomes cetuximab resistance in CC-CR. Both XAV-939, a tankyrase inhibitor, and ICG-001, a β-catenin-CBP inhibitor, augment the growth inhibitory effects of cetuximab. We propose that future trials in individuals with wild-type *KRAS/NRAS/BRAF* CRC should consider the levels of MIR100HG expression.

In summary, we have identified a complex circuitry underlying cetuximab resistance by upregulation of MIR100HG and its embedded miRNAs (see [Extended Data Fig. 10](#F10){ref-type="fig"}). miR-100 and miR-125b coordinately activate Wnt signaling by reducing expression of five negative regulators of Wnt signaling. miR-125b reinforces upregulation of MIR100HG by inhibiting GATA6 expression, which normally suppresses MIR100HG. We show that inhibition of Wnt signaling can overcome this mode of cetuximab resistance, underscoring the potential clinical relevance of the interactions between EGFR and Wnt signaling.

Data availability {#S9}
-----------------

RNA-Seq and small RNA-Seq data are available at the NCBI Gene Expression Omnibus (GEO) repository with accession code GSE82236. Whole-exome sequencing data are available at the GEO repository with accession code GSE76352. A Life Sciences Reporting Summary is available online.

Online Methods {#S10}
==============

2D and 3D cell culture {#S11}
----------------------

NCI-H508, Caco-2, SW403, SW948, HT29, SK-CO-1, DLD-1, SW480, SW837, SW48, SW620, LoVo, COLO205, T84, LS174T, NCI-H716, HCT8, HCT15, SW1116, RKO, COLO320DM, HuTu80, LS123, and HCT116 cell lines were from the American Type Culture Collection (ATCC). HCA-7, its derivatives CC and CC-CR, DiFi, GEO, LIM1215, and LIM2405 were maintained in the Coffey lab. The SNUC4 cell line was from the Korean Cell Line Bank and the V9P cell line was provided by John Mariadason (Olivia Newton-John Cancer Research Institute, Melbourne, Australia). HNSCC cell lines SCC25, its derived cetuximab-resistant sublines (CTX-R1, R3, R4, R5, R7, and R8), and UNC10 were maintained in Christine Chung\'s laboratory. All cell lines were confirmed to be free of mycoplasma contamination. Cells were grown in Dulbecco\'s Modified Eagle\'s Medium (DMEM, Corning) supplemented with 10% bovine growth serum, glutamine, nonessential amino acids, 100 U/ml penicillin and 100 μg/ml streptomycin (HyClone) in 5% CO~2~ at 37°C. 3D collagen cultures were set up using 3 layers of type-I collagen PureCol (Advanced BioMatrix) in triplicate as previously described^[@R14],[@R15]^. Human recombinant DKK1 (rDKK1) and DKK3 (rDKK3) are from R&D Systems. Drugs are used as follows: cetuximab (Merck KGaA), Wnt pathway inhibitor ICG-001 and XAV-939 (Selleck Chemicals). Colonies were counted by GelCount colony counter (Oxford Optronix).

RNA-Seq analysis {#S12}
----------------

Total RNA from cells embedded in collagen was isolated by TRIzol Reagent (Invitrogen) and then purified using RNeasy Mini Kit (Qiagen). The concentration and integrity of total RNA were estimated using the Qubit 2.0 Fluorometer (Invitrogen) and Agilent 2100 Bioanalyzer (Agilent Technologies), respectively. Polyadenylated RNAs were isolated using NEBNext Magnetic Oligo d(T)25 Beads. First strand synthesis was performed using NEBNext RNA First Strand Synthesis Module (New England BioLabs). Directional second strand synthesis was performed using NEBNext Ultra Directional Second Strand Synthesis Module. The NEBNext DNA Library Prep Master Mix Set for Illumina was used to prepare next-generation sequencing expression libraries per manufacturer\'s protocol. Accurate quantification for sequencing applications was determined using the qPCR-based KAPA Biosystems Library Quantification Kit (Kapa Biosystems). Paired-end (PE) sequencing (75bp) was performed on the NextSeq 500 sequencer (Illumina).

RNA-Seq reads were aligned to the human genome hg19 using TopHat2^[@R60]^, and the number of reads mapped to each gene was calculated by HTseq (<http://www-huber.embl.de/users/anders/HTSeq/>). Differentially expressed genes between CC and CC-CR were detected by edgeR based on negative binomial distribution^[@R61]^. The *p*-values were adjusted by Benjamini and Hochberg\'s multiple test correction procedures. Differential expression was determined based on fold-change (FC) and false discovery rate (FDR) with \|log~2~(FC)\| \>1 and FDR\<0.01.

Small RNA-Seq analysis {#S13}
----------------------

Approximately 1 μg of total RNA from each sample was utilized for small RNA library preparation using NEBNext Small RNA Library Prep Set for Illumina (New England BioLabs) following the manufacturer\'s protocol. Post PCR material was purified using QIAquick PCR Purification Kit (Qiagen). Post PCR yield and concentration of the prepared libraries were assessed using Qubit 2.0 Fluorometer and DNA 1000 chip on Agilent 2100 Bioanalyzer. Size selection of small RNA was done on the Pippin Prep instrument (Sage Science). Accurate quantification for sequencing applications was performed using the qPCR-based KAPA Biosystems Library Quantification Kit. Single end sequencing (50BP) was performed on a NextSeq 500 Sequencer (Illumina).

Adapters from 3′ end of small RNA-Seq reads were trimmed by Cutadpt (<http://code.google.com/p/cutadapt/>). Sequences shorter than 15 bp were excluded from the downstream analysis. Reads were aligned to the human genome hg19 using Bowtie. Mapped reads were annotated, and miRNA expression was quantified using ncPRO-seq (version v1.5.1)^[@R62]^ based on miRbase v19. Differentially expressed miRNAs between CC-CR and CC cells were detected by edgeR^[@R61]^. The *p*-values were adjusted by Benjamini and Hochberg\'s multiple test correction procedures. Differential expression was determined based on FC and FDR with \|log~2~(FC)\| \>1 and FDR \<0.01.

Whole-exome sequencing {#S14}
----------------------

DNA extraction was performed by the QIAamp DNA Mini Kit (Qiagen) following the manufacturer\'s instructions. The DNA was quantified by Nanodrop spectrophotometer (Thermo Fisher Scientific). Genomic DNA was sequenced using Illumina HiSeq 2500. Reads were aligned to the human genome hg19 with BWA, sorted, and indexed with SAMtools. Duplicated reads were marked by Picard (<http://picard.sourceforge.net/>). SNPs and Indels were called simultaneously on CC and CC-CR samples by SAMtools with base quality ≥30, reads with mapping quality ≥30, and mapping quality downgrading coefficient of 50. SNPs and Indels with strand bias *P*\<0.01, base quality bias *P\<*0.01, mapping quality bias *P\<*0.01, or end distance bias *P\<*0.01 were filtered out. Furthermore, SNPs within 3 bp around a gap were removed. SNPs and Indels were annotated, and their effects were predicted by snpEff and snpSift^[@R63]^. Strekla^[@R64]^ was used to detect SNVs and indels that were present at a significantly different frequency between CC and CC-CR samples with default parameters except turning off the depth filter for exome sequencing data.

Constructs, oligonucleotides, infection and transfection of human cell lines {#S15}
----------------------------------------------------------------------------

miRNA expression lentiviral vectors LeGO-cO:miR-100, LeGO-cO:miR-125b, LeGO-cO:miR-100/125b bicistron, and control empty vector were used as described previously^[@R12]^. Lentivirus produced in HEK293 cells was generated and collected using standard protocols^[@R12]^. GFP-positive infected cells were selected in Blasticidin S (10 μg/ml) followed by flow sorting. Stable miRNA knockdown was achieved by introducing the lentiviral miRNA sponge constructs that target either miR-100, miR-125b alone or both. Briefly, eight repeats of anti-sense miR-100 (5′-CACAAGTTCGGATCTACGGGTT-3′) or/and anti-sense miR-125b (5′-TCACAAGTTAGGGTCTCAGGGA-3′) were designed and synthesized following standard protocols^[@R65]^, and then cloned into the pGLV3/H1/GFP vector (GenePharma). A control sponge was used, which includes eight repeats of an artificial miRNA (5′-AAGTTTTCAGAAAGCTAACA-3′)^[@R66]^ that is not complementary to any known miRNA. GFP-positive infected cells were selected in puromycin (1 μg/ml) followed by flow sorting.

Human DKK1 expression vector pcDNA3-DKK1-FLAG was kindly provided by Dr. Stuart Aaronson (Mount Sinai School of Medicine). Human DKK3 expression vector pCS2-DKK3-flag was from Addgene (plasmid \#15496). Lentiviral-inducible expression constructs containing DKK1 or DKK3 under the control of a doxycycline-inducible promoter were constructed by transferring each ORF into the pInducer-20 lentiviral vector^[@R67]^. Infected cells were selected in G418 (200 μg/ml) to generate stable cell lines. Tetracycline-reduced FBS (Clontech) was substituted for all media for cells transduced with the pInducer-20 vectors. To induce expression of DKK1 or DKK3, 1 μg/ml doxycycline (Sigma-Aldrich) was added to the culture medium.

pcDNA3.1-GATA6 and pcDNA3.1-mutant (mut) GATA6 by site-directed mutagenesis were kindly provided by Dr. Christine A. Iacobuzio-Donahue (Memorial Sloan Kettering Cancer Center). GATA6 Silencer Select siRNAs (ID s5605, s5606) and the Silencer Select negative control siRNA were used for transient transfection (Life Technologies). GATA6 expression plasmids or siRNAs were transfected into indicated cells using Lipofectamine 2000 or RNAiMAX Reagent (Thermo Fisher Scientific), respectively. Experiments were performed 48 h after transfection.

For 3′ UTR luciferase reporter assay, the 3′ UTR fragments of DKK1, DKK3, ZNRF3, RNF43, and APC2 containing miR-100 or miR-125b putative target sites were amplified and cloned downstream of the SV40 promoter-driven *Renilla* luciferase cassette in psiCHECK-2 (Promega). For luciferase reporter assays to measure promoter activities, PCR products of sequential deletion fragments of human MIR100HG promoter were cloned into pGL3-Basic vector (Promega). A site-directed mutagenesis kit (Agilent Technologies) was used to mutate the miR-100, miR-125b, or GATA6 binding sites of these vectors. All sequences were confirmed by sequencing.

Quantitative RT-PCR {#S16}
-------------------

Analysis of mRNA and miRNA levels was performed on the StepOnePlus Real-Time PCR System (Applied Biosystems). For mRNA detection, cDNA was generated with the QuantiTect Reverse Transcription Kit (Qiagen). Diluted cDNA samples were amplified to establish a standard curve for calculation of relative target concentrations using Express SYBR GreenER qPCR SuperMix with Premixed ROX (Life Technologies). The housekeeping gene ACTB was used as an internal control. The primers for the genes of interest were synthesized by RealTimePrimers.com or Sigma-Aldrich ([Extended Data Table 9](#T9){ref-type="table"}). Analysis of lncRNA and miRNA levels was performed with the use of the TaqMan fast advanced master mix (Applied Biosystems). TaqMan lncRNA, miRNA, and Pri-miRNA expression assays (Life technologies) were used according to the manufacturer\'s instructions, with ACTB or U6 small nuclear RNA (U6 snRNA) as the internal control ([Extended Data Table 10](#T10){ref-type="table"}). The relative expression of RNAs was calculated using the comparative Ct method.

5′ Rapid amplification of cDNA ends (RACE) {#S17}
------------------------------------------

5′ RACE was used to determine transcriptional initiation sites of lncRNA MIR100HG using FirstChoice RLM-RACE Kit (Thermo Fisher Scientific), and Zero Blunt TOPO PCR Cloning Kit (Life Technologies) was used for sequencing according to the manufacturer\'s instructions. Two reverse primers for the TSS of MIR100HG were used in a nested PCR with the two 5′ primers from the kit. Outer primer: 5′-AAACCGGGCCCTCCAGTTCACTAT C-3′; Inner primer: 5′-TCTTTTCCATCCCCTTTGCATGTGG-3.

Western blot analysis {#S18}
---------------------

Whole cell lysates were prepared using RIPA buffer supplemented with protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor (Roche). The nuclear extract was isolated using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific). Protein concentration was determined using the BCA Protein Assay Kit (Thermo Fisher Scientific). Primary antibodies were against DKK1 (Santa Cruz sc-25516), ZNRF3 (sc-86958), RNF43 (sc-165398), GATA6 (sc-7244), Lamin A/C (sc-7292), and GAPDH (sc-20357); DKK3 (Abcam \#2459), APC2 (Abcam \#80018), ZNRF3 (Abcam \#122353), RNF43 (Abcam \#84125), and p-EGFR Y1068 (Abcam \#5644); β-Catenin (BD Biosciences \#610154); EGFR (Millipore \#06-847) and p-LRP6 (Millipore \#07-2187); ERK1/2 (Cell Signaling Technology, CST, \#4695), p-ERK1/2 (CST \#4370), AKT (CST \#9272), p-AKT (CST \#4060), cleaved Caspase-3 (CST \#9664), Cyclin-D1 (CST \#2978), BIM (CST \#2933), p-β-catenin (S552) (CST \#9566), LRP6 (CST \#2560), and GATA6 (CST \#5851); β-actin (Sigma-Aldrich A1978). Immunoreactivity was detected and the signals were analyzed under nonsaturating conditions with an image densitometer (ChemiDoc MP Imager, Bio-Rad) and Image Lab software (Bio-Rad). All immunoblot analyses were performed at least three times.

Immunofluorescent staining {#S19}
--------------------------

Immunofluorescent staining and confocal analysis were performed as described^[@R14]^. Primary antibodies were against cleaved Caspase-3 antibody (Abcam \#2302), Ki-67 (Dako M7240), p-β-catenin (Y489) (Developmental Studies Hybridoma Bank, IA), and GATA6 (CST \#5851). Alexa Fluor 568 Phalloidin was from Life Technologies. Secondary antibodies included Alexa Fluor 488, 568, or 647-conjugated goat anti-mouse or anti-rabbit IgGs (Life Technologies). Nuclei were stained with Hoechst 33342. Slides were mounted with Prolong Gold Antifade Reagent (Life Technologies) prior to imaging on a Zeiss LSM 710 confocal microscope. Quantification was done by manually counting at least 5 randomly chosen high power fields (HPFs) per sample.

Luciferase reporter assays {#S20}
--------------------------

For 3′ UTR luciferase reporter assays, indicated cells cultured in 24-well plates were co-transfected with miR-100 or miR-125b mimic or negative control (Ambion) and indicated psiCHECK-2-3′ UTR wild-type or mutant plasmids using Lipofectamine 2000 (Thermo Fisher Scientific). *Renilla* and firefly luciferase activities were measured after 48 h with the dual-luciferase reporter assay system (Promega). *Renilla* luciferase activity was normalized to firefly activity and presented as relative luciferase activity.

For luciferase reporter assay to measure promoter activities, indicated cells were co-transfected with pGL3-MIR100HG promoter fragment, pRL-SV40 *Renilla* luciferase reporter, and pcDNA3.1-GATA6 or mut GATA6 expression plasmid or empty vector control. The firefly and *Renilla* luciferase activity was measured with the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to *Renilla* activity and presented as relative luciferase activity. All assays were performed in triplicate three times.

Chromatin immunoprecipitation (ChIP) {#S21}
------------------------------------

ChIP assays were performed using a Pierce Agarose ChIP Kit (Thermo Fisher Scientific) following the manufacturer\'s instructions, and ChIP-enriched DNA samples were analyzed by qPCR. Cells were cross-linked with 1% formaldehyde for 10 min at room temperature and quenched in glycine. Rabbit anti-GATA6 antibody (CST \#5851) or normal rabbit IgG (BD Biosciences) were used for immunoprecipitation. The DNA was recovered and subjected to qPCR to amplify the binding sites of the MIR100HG promoter region. Data are presented as relative enrichment normalized to control IgG. The qPCR primer sets are: for GATA-binding site-2 (-1198 upstream of the TSS): forward, 5′-ACCTATCTCTGCTACTTATTTTATG-3′, reverse, 5′-CTATTTATCAGCACAGTTACTGG -3′; distal region primer sets: forward, 5′-GAATGCAGTAGTGGCTAG GAATG-3′, reverse, 5′-CTAACTCTCTAGGCTGTTATCTG-3′.

Electrophoretic mobility shift assay (EMSA) {#S22}
-------------------------------------------

Nuclear and cytoplasmic proteins were extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Fisher Scientific). LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific) was used according to the manufacturer\'s protocol. Double-stranded biotin-labeled probe (5′-GCTCTCTATTTATCA GCACAGTTA-biotin-3′) was used, which corresponds to GATA-binding site-2 of the human MIR100HG gene promoter (-1198 upstream of the TSS). Nuclear extracts (8 μg) were incubated with labeled probe, poly (dI-dC), and the binding buffer for 30 min at room temperature. For supershift experiments, 1 μg of monoclonal rabbit anti-GATA6 (CST \#5851) was added to the reaction mixture before the addition of labeled probe. For the binding competition experiment, an excess (200-fold) of unlabeled cold competitor probe or mutant probe (5′-GCTCTCTGCCCGCTGATACAGTTA-3′) was added into the reaction mixture. Bound DNA complexes were resolved on polyacrylamide gels and transferred to a nylon membrane (Thermo Fisher Scientific). Nylon membranes were cross-linked and chemiluminescent detection was performed.

Immunohistochemistry (IHC) {#S23}
--------------------------

IHC for target molecules was performed on serial sections from tumor tissues of nude mice xenografts and CRC patients. Tissue sections were deparaffinized, subjected to antigen retrieval using target antigen retrieval solution (Dako), and incubated with primary antibodies against Ki67 (Dako M7240), cleaved Caspase-3 (CST \#9661), β-catenin (BD Biosciences \#610154), GATA6 (Abcam \#22600), DKK1 (Abcam \#61034), DKK3 (Abcam \#115869), ZNRF3 (Abcam \#122353), RNF43 (Abcam \#129401), and APC2 (Abcam \#113370). Then sections were incubated with Envision System HRP-labeled polymer anti-rabbit or anti-mouse secondary antibodies (Dako). The results of IHC were scored by two independent observers. Ki-67 and cleaved Caspase-3 staining was quantified by calculating positively stained cells in at least 5 randomly chosen HPFs of each sample. Quantification of other molecules was based on intensity and extent of staining according to the histological scoring method as previously described^[@R68]^.

*In vivo* tumor growth in xenograft model {#S24}
-----------------------------------------

*In vivo* cetuximab treatment was performed using 6∼8-week-old female athymic BALB/c nude mice. All experiments were conducted under protocols approved by the Fourth Military Medical University Institutional Animal Care and Use Committee. Suspensions of the corresponding cells were subcutaneously injected into the flanks (6×10^6^ tumor cells/150 μl PBS per spot; 6-8 mice in each group). Animals were weighed, and the tumor size was measured using bilateral caliper measurements. Tumor volume was calculated using the formula: Tumor maximum diameter (L) × the right angle diameter to that axis (W)^2^/2. When the tumors reached the determined size (around 100 mm^3^), mice were randomized into control and treatment groups. Cetuximab treatment was given at a dose of 1 mg/mouse, intraperitoneal (i.p.) injection, every 3 days. For Wnt pathway inhibitor ICG-001 *in vivo* treatment, the sodium phosphate form of ICG-001, synthesized by Vanderbilt Institute of Chemical Biology (VICB) Synthesis Core, was administered at a dose of 150 mg/kg body weight, i.p. injection every day. *In vivo* imaging system (IVIS, PerkinElmer) was used to detect GFP fluorescence in tumor-bearing mice. After 4 weeks of treatment, mice were sacrificed according to institutional ethical guidelines. Postmortem examination included tumor size and weight measurements, and then tumors were paraffin-embedded to perform hematoxylin and eosin (H&E) staining. The sample size for the experiments was based on the pilot studies and determined to ensure a power at 0.8 with type 1 error (α) at 0.05 of expected difference. Postmortem examination and data analysis were done by two investigators blinded to the group allocations.

Human CRC samples and subjects {#S25}
------------------------------

All human CRC samples were obtained from the Xijing Hospital of Digestive Diseases. The study was approved by the Ethics Committee of Xijing Hospital with written informed consent obtained from all subjects. The pathological status of the specimens was provided by the Department of Pathology. In total, we analyzed 10 pairs of tumor specimen pre- and post-cetuximab treatment. Pre-cetuximab treated specimens were retrospectively obtained during surgical or biopsy under colonoscopy on subjects with CRC. After computed tomography (CT) of tumor lesions demonstrated tumor re-growth (disease progression) following initial response to cetuximab-based therapy, post-cetuximab treated specimens were collected whenever possible at the time of progression. RNA was extracted with RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Ambion). IHC and *FISH* analyses were performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue *sections.* Blind evaluation was done by two pathologists.

Fluorescence *in situ* hybridization (FISH) assays {#S26}
--------------------------------------------------

Locked nucleic acid-*in situ* hybridization (LNA-ISH) with tyramide signal amplification (TSA) was performed to detect lncRNA and miRNA as previously described^[@R13],[@R69]^. All LNA probes were synthesized (Exiqon) including double biotin-labeled probe against MIR100HG, double digoxigenin (DIG)-labeled probe against miR-125b, double fluorescein-labeled probe against miR-100, DIG-labeled probe against U6 snRNA, and DIG-labeled scramble probe. Anti-Digoxigenin HRP Conjugate, anti-Fluorescein HRP Conjugate, Streptavidin-HRP Conjugate, and TSA Cy3 and Fluorescein Kit (all from PerkinElmer) were used for TSA methods. Confocal fluorescence microscopy was performed using a Zeiss LSM 710 confocal microscope.

For detection of *MET* amplification, *MET*/*CEP7* dual-color probes (Cytotest) were used for recognizing the *MET* gene status following the manufacturer\'s protocol. Analysis was according to the University of Colorado Cancer Center (UCCC) criteria. A *MET*/*CEP7* ratio was established based on counting at least 200 cells.

Targeted Sanger sequencing of *KRAS, NRAS* and *BRAF* {#S27}
-----------------------------------------------------

*KRAS*/*NRAS*/*BRAF* mutations had been excluded in tumor specimens obtained prior to treatment with cetuximab. This study was carried out on 12 FFPE blocks of colorectal carcinomas (10 blocks obtained after disease progression upon cetuximab treatment and case 2 and 4 blocks before treatment). Genomic DNA was isolated using QIAamp DNA FFPE Tissue Kit (QIAGEN). Oncogenic alleles of *KRAS* (codon G12, G13, Q61, K117, and A146), *NRAS* (codon G12, G13, and Q61), and *BRAF* (codon G465, G468, Y472, D593, F594, L596, L597, T598, V600, and K601) were sequenced by targeted Sanger sequencing with PCR primers listed ([Extended Data Table 11](#T11){ref-type="table"}). The PCR products were then sequenced using BigDye Terminator 3.1 Cycle Sequencing Kit on a 96-capillary 3730XL DNA Sequencer (Applied Biosystems).

Statistical analysis {#S28}
--------------------

Statistical analysis was performed by the SPSS 18.0 (SPSS Inc.) and R (version 3.3.1). The statistical significance between data sets was expressed as *P*-values, and *P*\<0.05 was considered statistically significant. Two-tailed unpaired or paired Student\'s *t* test, ANOVA (Dunnett\'s or LSD post-hoc test), non-parametric signed rank test, Mann-- Whitney *U* test, and Pearson correlation coefficients were used according to the type of experiment.

For Pearson correlation of MIR100HG expression with 64-gene Wnt scores and RAS_AZ scores on 458 CRCs, the Log~2~ expression values of MIR100HG were obtained on 458 CRC tumors (10 samples without suitable microarray data were excluded from 468 CRCs previously reported^[@R19],[@R70]^). A set of 64 "consensus" β-catenin (upregulated) targeted genes were adopted from a recent study^[@R71]^, and a mean Log~2~ expression of the 64 genes was calculated as the Wnt/β-catenin pathway score on 458 CRC samples as previously described^[@R19]^. The RAS_AZ signature score, which measures MEK activation as a downstream index of RAS activity, was previously developed^[@R20]^ and was pre-calculated on 458 CRC samples^[@R19],[@R70]^. For comparison of the Wnt scores between CC and CC-CR, the 64-gene Wnt scores (Log~2~ expression) were calculated for CC and CC-CR (each with 3 replicates) similarly as described above and then subjected to the two-tailed unpaired Student\'s *t* test.

RNA-Seq and small RNA-Seq data of CRC was obtained from TCGA Firehose developed by the Broad GDAC ([https://confluence.broadinstitute.org/display/GDAC/](http://https://confluence.broadinstitute.org/display/GDAC/) Dashboard-Stddata). mRNA expression array data of CRC/colon cancer was acquired from published studies (GEO accession: GSE14333, GSE39582)^[@R72],[@R73]^. The gene expression abundances were Log~2~ transformed, and Pearson correlation coefficients were used to measure the correlation between MIR100HG and miR-100, miR-125b, and let-7a. Mann-Whitney *U* test was used to determine the expression difference of MIR100HG in the lower (0-25%) and the higher (\>75%) quartiles of GATA6 expression.

Extended Data {#S29}
=============

![Establishment of cetuximab-resistant cells in 3D culture.\
**(a)** Five thousand cells/ml were cultured in type-1 collagen for 17 days. Fresh medium was added with different concentrations of CTX every 2 days, and colony number was determined using a GelCount plate reader. n=2 independent experiments performed in triplicate. **(b)** Twelve-day old CC and CR were treated with CTX (10 μg/ml) for 3 days. Representative images from 3 independent experiments are shown. Scale bars, 1000 μm. **(c)** Left: Representative fluorescence images of GFP signals captured from subcutaneous tumors, generated by injection of CC and CC-CR stably transduced with GFP-expressing lentivirus. Right: Quantification of radiant efficiency from tumors. n=8. \*\**P*\<0.01 by paired Student\'s *t* test. **(d)** Representative H&E staining of the tumor xenografts from the indicated groups. Scale bar, 100 μm. **(e)** Quantification of IHC staining in [Fig. 1g](#F12){ref-type="fig"}. n=8 mice. \*\**P*\<0.01 by Student\'s *t* test. **(f)** CC and CC-CR cells grown on Transwell filters were incubated with Alexa Fluor 488-labeled C225 mAb directed against the extracellular domain of EGFR and then stained for F-actin (Phalloidin) and nuclei (DAPI). Scale bars, 20 μm. Data represent mean ± s.d. in a, c, and e.](nihms905237f1){#F1}

![MIR100HG and miR-100/125b overexpression in cetuximab-resistant colorectal cancer cell lines.\
**(a)** qRT-PCR showing upregulation of pri-miR-100 and pri-miR-125b-1 in CC-CR compared to CC grown in 3D. In CC-CR, cells were treated with CTX (CTX+, 3 μg/ml) or normal culture medium (CTX-) for consecutive 14 days in 3D. **(b)** qRT-PCR showing upregulation of pri-let-7a-2 expression in CC-CR but unchanged expression of mature let-7a between the 2 cell lines. n=3 independent experiments performed in triplicate in a and b. Data represent mean ± s.d. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with CC. **(c)** Left: a schematic diagram showing the PCR primers used in the 5′ RACE. Right: MIR100HG TSS was validated by 5′ RACE nested PCR in CC-CR with subsequent sequencing of the cloned fragments. Arrow indicates band of expected size. M, DNA marker. **(d)** Scatter plots of MIR100HG versus let-7a expression in TCGA CRC data repository. No correlation was found between those 2 molecules. **(e, f)** Expression of MIR100HG and miR-100/125b negatively correlates with cetuximab growth inhibition regardless of *KRAS*/*BRAF* mutational status. (e) Scatter plot of MIR100HG and miR-100/125b expression versus cetuximab inhibition rate in a panel of 30 CRC cell lines. (f) Twenty-one cell lines harbor *KRAS* or *BRAF* mutation, and 9 cell lines are *KRAS*/*BRAF* wild-type (WT). Pearson correlation coefficients (*r*) and *P* values are shown.](nihms905237f2){#F2}

![MIR100HG and miR-100/125b expression in head and neck squamous cell cancer cell lines and modulation of miR-100 and/or miR-125b in CC and CC-CR cells.\
**(a)** qRT-PCR analysis of MIR100HG, miR-100, and miR-125b expression among the CTX-sensitive head and neck squamous cell carcinoma (HNSCC) cell line SCC25 and its derived CTX-resistant sublines (CTX-R1, R3, R4, R5, R7, and R8) upon continuous exposure to cetuximab, as well as UNC10, a *de novo* CTX-resistant cell line. n=3 independent experiments performed in triplicate. \**P*\<0.05, \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with SCC25. **(b)** qRT-PCR of indicated miRNA expression in CC stably overexpressing miR-100, miR-125b, or Bicistron. **(c)** qRT-PCR of indicated miRNA expression in CC-CR stably expressing miR-100 sponge (100-Sp), miR-125b sponge (125b-Sp), or bicistron sponge (Bicistron-Sp). Values were normalized to U6 snRNA. n=3 experiments performed in triplicate. \*\**P*\<0.01 by Student\'s *t* test. **(d, e)** Quantification of Ki-67 and Cleaved Casp-3 in [Fig. 3c and d](#F14){ref-type="fig"}. n=4 independent experiments. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. Data represent mean ± s.d. n.s., not significant.](nihms905237f3){#F3}

![miR-100 and miR-125b cooperativity drives cetuximab resistance in colorectal cancer and head and neck squamous cell cancer cell lines.\
**(a)** Caco-2 cells stably overexpressing Bicistron or control (miR-CTL) were cultured in 3D for 5 days and treated with CTX (50 μg/ml) for 24 h. Immunofluorescence was performed for Cleaved Casp-3 (cyan) and Ki-67 (magenta) with quantification shown on the right. Scale bar, 50 μm. n=3 independent experiments. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. **(b)** DLD-1 cells stably expressing Bicistron-Sp or control (CTL-Sp) were cultured in 3D for 10 days and treated with CTX (200 μg/ml) for 24 h. Staining of Cleaved Casp-3 (cyan) and Ki-67 (magenta) were shown. Scale bars, 50 μm. Quantification is shown on the right. n=3 independent experiments. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. **(c, d)** Indicated cells were grown in 3D in normal medium (CTL) or treated with CTX (50 μg/ml for Caco-2, and 200 μg/ml for DLD-1) in 3D. The resultant colonies were counted. n=2 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with miR-CTL or CTL-Sp. **(e)** Left: CTX-R7 cells stably expressing miR-100 and/or miR-125b sponges were grown in normal medium (CTL) or treated with CTX (30 μg/ml). Cell viability was measured by cell counting kit-8 (CCK-8) assays after 72 h. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with CTL-Sp. Middle: qRT-PCR analysis of Wnt target genes in the stable bicistron sponge-transduced CTX-R7 cells. n=2 independent experiments performed in triplicate. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. Right: CTX-R7 cells were treated with CTX (30 μg/ml) and/or ICG-001 (2 μM) for 72 h, and cell viability was measured by CCK-8 assays. n=2 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by by LSD post-hoc test. Data represent mean ± s.d. n.s., not significant.](nihms905237f4){#F4}

![Effects of differential modulation of miR-100 and/or miR-125b on cetuximab responsiveness in CC and CC-CR *in vivo*.\
**(a, b)** Quantification of radiant efficiency from tumors (n=8) represented on [Fig. 3e and f](#F14){ref-type="fig"}. \*\**P*\<0.01 by paired Student\'s *t* test. **(c-f)** Representative IHC images and quantification of Ki-67 and Cleaved Casp-3 from indicated xenografts (n=8) treated with CTX. Scale bars, 50 μm. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test in e and f. Data represent mean ± s.d. in a, b, e, and f. n.s., not significant.](nihms905237f5){#F5}

![miR-100/125b coordinately represses five Wnt/β-catenin negative regulators, resulting in increased Wnt signaling.\
**(a)** Left: Wnt activation in CC and CC-CR cells was measured by the 64 Wnt/β -catenin target genes (Wnt signature score). \*\**P*\<0.01 by Student\'s *t* test. Right: Scatter plots of MIR100HG expression versus 64-gene Wnt signature score on 458 CRC. Pearson correlation coefficients (*r*) and *P* values are shown. **(b)** Immunoblots of DKK1, DKK3, ZNRF3, RNF43, and APC2 levels from 3D cell lysates of CC and CC-CR. In CC-CR, cells were treated with CTX (CTX+, 3 μg/ml) or normal culture medium (CTX-) for 14 days in 3D before protein extraction. Representative of 3 independent experiments. **(c)** Top : representative IHC images of DKK1, DKK3, ZNRF3, RNF43, and APC2 in CC and CC-CR xenografts (n=8). Bottom: measurement of protein expression, \*\**P*\<0.01 by Mann-Whitney *U* test. **(d)** Dual luciferase assays of genes predicted to be regulated by miR-100 or miR-125b in Caco-2. *Renilla* luciferase activity was normalized to firefly activity. n=2 independent experiments. \*\**P*\<0.01 by Student\'s *t* test. **(e)** Immunoblots of indicated proteins in stable miRNA-transduced Caco-2 and sponge (Sp)-transduced HuTu80. Representative of 2 independent experiments. **(f)** Immunoblot of nuclear and cytoplasmic extracts for β-catenin and p-β-catenin (S552). Loading controls were GAPDH for cytoplasmic fractions and Lamin A/C for nuclear fractions. **(g)** CC and CC-CR in 3D were treated with CTX (10 μg/ml) and/or Wnt3a (100 ng/ml). Immunoblots of indicated proteins after 48 h of treatment are shown. Representative of 3 independent experiments. **(h)** qRT-PCR analysis of Wnt targets CCND1, CD44, FOSL1, and NKD1 mRNAs at indicated time points following CTX (10 μg/ml) treatment in 3D. n=2 independent experiments performed in triplicate. \*\**P*\<0.01 by two-way ANOVA test. Data represent mean ± s.d. in a, c, d, and h.](nihms905237f6){#F6}

![Effects of differential modulation of miR-100 and/or miR-125b on nuclear β-catenin expression levels.\
**(a)** Immunoblots for β-catenin from nuclear fractions in the CC and Caco-2 cells overexpressing miR-100 and/or miR-125b, or CC-CR, DLD-1 and CTX-R7 cells expressing miR-100 and/or miR-125b sponges. Lamin A/C served as the control for nuclear fractions. Representative of 2 independent experiments. **(b)** Representative IHC of β-catenin in the indicated xenografts (n=8). Scale bars: 50 μm. Quantification of nuclear β-catenin positive cells is shown. Data represent mean ± s.d. \*\**P*\<0.01 by Student\'s *t* test.](nihms905237f7){#F7}

![Blockade of Wnt signaling restores cetuximab responsiveness to cetuximab-resistant cells.\
**(a, b)** Left: CC-CR doxycycline (Dox)-on DKK1 or DKK3 cells were cultured in the presence or absence of Dox (1 μg/ml) and harvested at 48 h. Total cell lysates and conditioned media were harvested and subjected to immunoblot analysis. Right: indicated cells were grown in 3D in normal medium or treated with CTX (3 μg/ml). The resultant colonies were counted after 18 days. n=3 experiments performed in triplicate. \*\**P*\<0.01 by Student\'s *t* test. **(c)** CC-CR cells were grown in 3D in normal medium (CTL), treated with CTX (3 μg/ml) or in combination with recombinant DKK1 (rDKK1) and DKK3 (rDKK3) in 3D every 2 days. The resultant colonies were stained after 18 days for Cleaved Casp-3 (green) and Ki-67 (red). Scale bar, 50 μm. Quantification was shown. n=3 independent experiments. **(d)** Immunoblots for β-catenin from nuclear and cytoplasmic fractions of indicated cells upon CTX (10 μg/ml) treatment. Loading controls were GAPDH for cytoplasmic fractions and Lamin A/C for nuclear fractions. **(e)** CC-CR were treated with CTX (3 μg/ml), and/or XAV-939 (1, 5, 10 μM), and/or ICG-001 (1, 2.5, 5 μM) in 3D for 18 days, and colony number was determined. n=3 experiments performed in triplicate. **(f)** DLD-1 and HCT8 cells were treated with CTX (200 μg/ml) and/or ICG-001 (4 μM) for 14 days in 3D, and colony number was determined. n=2 independent experiments performed in triplicate. **(g)** Quantification of radiant efficiency from tumors (n=6) represented on [Fig. 4i](#F15){ref-type="fig"}. \*\**P*\<0.01 by paired Student\'s *t* test. **(h)** Representative IHC images and quantification of Ki-67 and Cleaved Casp-3 from CC-CR xenografts (n=6) treated with control saline (CTL), or CTX (1 mg/mouse, i.p. injection, every 3 days), and/or ICG-001 (150 mg/kg, i.p. injection, daily). Scale bar, 50 μm. \**P*\<0.05, \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test in c, e, and h, and one-way ANOVA followed by LSD post-hoc test in f. Data represent mean ± s.d. in a-c and e-h. n.s., not significant.](nihms905237f8){#F8}

![A double-negative feedback loop between MIR100HG/miR-125b and GATA6. **(a)** Immunoblots of GATA6 expression in CC transfected with 2 independent siRNAs against GATA6 or control siRNA (siCTL). **(b)** Immunoblots of GATA6 expression in CC-CR transfected with either pcDNA3.1-GATA6 (WT GATA6), or pcDNA3.1-mutant GATA6 (MUT GATA6), or empty vector (CTL). **(c)** Luciferase reporter assays were performed in HuTu80 by co-transfection of pGL3-MIR100HG promoter luciferase reporter with increasing concentrations of pcDNA3.1-GATA6, and a *Renilla* control. Luciferase activity was normalized to *Renilla* values. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test. **(d)** The luciferase vector pGL3 driven by either wild-type, deletion, or mutant (MUT) promoter was transfected in HuTu80, and luciferase activity was measured. n=3 independent experiments. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. **(e)** ChIP assays were performed with anti-GATA6 antibody or control IgG in CC-CR overexpressing either WT GATA6, MUT GATA6, or CTL. The abundance of DNA within the MIR100HG promoter region was assessed by qRT-PCR with a primer pair spanning the GATA-binding site 2. A primer pair 6.4 kb distal to the MIR100HG promoter (Distal) was used as control. Data are presented as relative enrichment normalized to control IgG. \*\**P*\<0.01 by one-way ANOVA followed by LSD post-hoc test. **(f)** EMSA using nuclear extracts from CC and the indicated probes. Ab, antibody. Representative of 3 independent experiments. **(g)** Luciferase reporter analysis of a wild-type (WT) or MUT GATA6 3′ UTR activity upon addition of synthetic miR-125b in Caco-2. n=2 independent experiments. \*\**P*\<0.01 by Student\'s *t* test. **(h)** Immunoblots of GATA6 in stable miR-125b-transduced Caco-2 and 125b-Sp-transduced HuTu80. **(i)** Box plots showing MIR100HG expression in the lower (\<25%) and the higher (\>75%) quartiles of GATA6 expression from GEO CRC datasets GSE14333 and GSE39582. \*\**P*\<0.01 by Mann--Whitney *U* test. **(j)** *MET* genomic status detected by FISH assay. There was no obvious change in *MET* copy number in 10 paired tumor specimens pre- and post-cetuximab treatment. Representative images are shown. Red, *MET* locus; green, chromosome 7 centromere (*CEP7*). Scale bar, 20 μm. Data represent mean ± s.d. in c-e and g.](nihms905237f9){#F9}

![Model of a new mode of acquired and *de novo* cetuximab resistance. We propose a complex circuitry in which the lncRNA MIR100HG through embedded miR-100 and miR-125b confers cetuximab resistance by targeting and decreasing expression of five negative regulators of Wnt signaling, DKK1, DKK3, ZNRF3, RNF43, and APC2. This results in increased Wnt signaling and cetuximab resistance; this resistance can be overcome by blockade of Wnt signaling. We present evidence that GATA6 represses MIR100HG expression, but that miR-125b targets GATA6 to relieve this repression.](nihms905237f10){#F10}
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Original images of immunoblots with molecular weight standards.
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  Chr     Pos        Ref          Alt            Type                                                                                                                                                                                                                                                                                              AAchange                                                DNAchange                                                                 RefseqID                                                                                                               Gene                                                             CC_GT      CC_CR_GT
  ------- ---------- ------------ -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------- ----------
  chr1    1.17E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   T875I;T895I                                             aCc/aTc;aCc/aTc                                                           NM_001007237.1;NM_001542.2                                                                                             IGSF3;IGSF3                                                      Homo_ref   Homo_ALT
  chr16   74537530   C            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   A214S;A225S;A225S                                       Gcc/Tcc;Gcc/Tcc;Gcc/Tcc                                                   NM_001145666.1;NM_001145667.1;NM_012201.5                                                                              GLG1;GLG1;GLG1                                                   Homo_ref   Homo_ALT
  chrX    48762192   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   I332V;I332V                                             Att/Gtt;Att/Gtt                                                           NM_001042498.2;NM_005660.1                                                                                             SLC35A2;SLC35A2                                                  Homo_ref   Homo_ALT
  chrX    1.34E+08   C            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                   R22I;R22I;R22I;R22I                                     aGa/aTa;aGa/aTa;aGa/aTa;aGa/aTa                                           NM_001166600.2;NM_001166599.2;NM_145284.5;NM_001170756.1                                                               FAM122B;FAM122B;FAM122B;FAM122B                                  Homo_ref   Homo_ALT
  chrX    1.35E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   I1667M                                                  atA/atG                                                                   NM_153834.3                                                                                                            GPR112                                                           Homo_ref   Homo_ALT
  chr1    1254773    G            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   A111D;A117D;A82D                                        gCc/gAc;gCc/gAc;gCc/gAc                                                   NM_017871.5;NM_001256456.1;NM_001256460.1                                                                              CPSF3L;CPSF3L;CPSF3L                                             Homo_ref   Heter
  chr1    17740089   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   R384H;R384H                                             cGt/cAt;cGt/cAt                                                           NM_001136204.2;NM_018715.3                                                                                             RCC2;RCC2                                                        Homo_ref   Heter
  chr1    32653705   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R250W                                                   Cgg/Tgg                                                                   NM_175852.3                                                                                                            TXLNA                                                            Homo_ref   Heter
  chr1    47024318   G            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   R402C;R443C                                             Cgc/Tgc;Cgc/Tgc                                                           NM_001135553.2;NM_003684.5                                                                                             MKNK1;MKNK1                                                      Homo_ref   Heter
  chr1    51210391   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   L142V                                                   Tta/Gta                                                                   NM_007051.2                                                                                                            FAF1                                                             Homo_ref   Heter
  chr1    93303020   C            T              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 R179\*                                                  Cga/Tga                                                                   NM_000969.3                                                                                                            RPL5                                                             Homo_ref   Heter
  chr1    1.46E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   G410E                                                   gGa/gAa                                                                   NM_144698.3                                                                                                            ANKRD35                                                          Homo_ref   Heter
  chr1    1.55E+08   T            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)   M411K;M427K;M427K;M427K;M427K;M427K;M427K;M427K;M437K   aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg;aTg/aAg   NM_001261466.1;NM_207191.2;NM_001261465.1;NM_003815.4;NM_207195.2;NM_207194.2;NM_207196.2;NM_207197.2;NM_001261464.1   ADAM15;ADAM15;ADAM15;ADAM15;ADAM15;ADAM15;ADAM15;ADAM15;ADAM15   Homo_ref   Heter
  chr1    1.86E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   K263E;K272E;K295E                                       Aaa/Gaa;Aaa/Gaa;Aaa/Gaa                                                   NM_001164246.1;NM_001164245.1;NM_017847.5                                                                              C1orf27;C1orf27;C1orf27                                          Homo_ref   Heter
  chr1    2.27E+08   C            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   E690D                                                   gaG/gaT                                                                   NM_001618.3                                                                                                            PARP1                                                            Homo_ref   Heter
  chr1    2.49E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   G293R                                                   Ggg/Agg                                                                   NM_024836.1                                                                                                            ZNF672                                                           Homo_ref   Heter
  chr2    56420411   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P359L                                                   cCg/cTg                                                                   NM_001080433.1                                                                                                         CCDC85A                                                          Homo_ref   Heter
  chr2    65541153   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   A244T;A247T                                             Gcg/Acg;Gcg/Acg                                                           NM_001128210.1;NM_181784.2                                                                                             SPRED2;SPRED2                                                    Homo_ref   Heter
  chr2    84668385   G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P173T                                                   Cct/Act                                                                   NM_003849.3                                                                                                            SUCLG1                                                           Homo_ref   Heter
  chr2    98999879   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   N142D                                                   Aac/Gac                                                                   NM_001298.2                                                                                                            CNGA3                                                            Homo_ref   Heter
  chr2    99797317   T            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D43V                                                    gAt/gTt                                                                   NM_138798.1                                                                                                            MITD1                                                            Homo_ref   Heter
  chr2    1.44E+08   G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S217I                                                   aGt/aTt                                                                   NM_018460.3                                                                                                            ARHGAP15                                                         Homo_ref   Heter
  chr2    1.6E+08    G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S2108Y                                                  tCc/tAc                                                                   NM_013450.2                                                                                                            BAZ2B                                                            Homo_ref   Heter
  chr2    1.98E+08   A            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   F317I;F317I                                             Ttc/Atc;Ttc/Atc                                                           NM_001206774.1;NM_012086.4                                                                                             GTF3C3;GTF3C3                                                    Homo_ref   Heter
  chr2    2.36E+08   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Y479F                                                   tAc/tTc                                                                   NM_014521.2                                                                                                            SH3BP4                                                           Homo_ref   Heter
  chr3    30713286   G            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   G204D;G229D                                             gGc/gAc;gGc/gAc                                                           NM_003242.5;NM_001024847.2                                                                                             TGFBR2;TGFBR2                                                    Homo_ref   Heter
  chr3    48604415   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   N2717K                                                  aaT/aaG                                                                   NM_000094.3                                                                                                            COL7A1                                                           Homo_ref   Heter
  chr3    48604422   C            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S2715I                                                  aGt/aTt                                                                   NM_000094.3                                                                                                            COL7A1                                                           Homo_ref   Heter
  chr3    49689732   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A915T                                                   Gca/Aca                                                                   NM_003458.3                                                                                                            BSN                                                              Homo_ref   Heter
  chr3    49765037   G            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   R117S;R282S;R282S                                       Cgt/Agt;Cgt/Agt;Cgt/Agt                                                   NM_001006115.2;NM_001242829.1;NM_153273.3                                                                              IP6K1;IP6K1;IP6K1                                                Homo_ref   Heter
  chr3    75788432   T            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Q114H                                                   caA/caT                                                                   NM_001128223.1                                                                                                         ZNF717                                                           Homo_ref   Heter
  chr3    1.01E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   I247T                                                   aTc/aCc                                                                   NM_016247.3                                                                                                            IMPG2                                                            Homo_ref   Heter
  chr3    1.88E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   A303T;A303T                                             Gca/Aca;Gca/Aca                                                           NM_001167671.1;NM_005578.3                                                                                             LPP;LPP                                                          Homo_ref   Heter
  chr3    1.9E+08    T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   W653R                                                   Tgg/Cgg                                                                   NM_001167931.1                                                                                                         IL1RAP                                                           Homo_ref   Heter
  chr4    5577982    T            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   E1006V;E1086V                                           gAg/gTg;gAg/gTg                                                           NM_001166136.1;NM_147127.4                                                                                             EVC2;EVC2                                                        Homo_ref   Heter
  chr4    74021398   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V317A;V317A                                             gTg/gCg;gTg/gCg                                                           NM_198889.1;NM_032217.3                                                                                                ANKRD17;ANKRD17                                                  Homo_ref   Heter
  chr4    89709004   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                   D37N;D391N;D51N;D65N;D65N                               Gac/Aac;Gac/Aac;Gac/Aac;Gac/Aac;Gac/Aac                                   NM_001265580.1;NM_014883.3;NM_001265578.1;NM_001265579.1;NM_001015045.2                                                FAM13A;FAM13A;FAM13A;FAM13A;FAM13A                               Homo_ref   Heter
  chr4    1.26E+08   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   Q1212R;Q1391R                                           cAg/cGg;cAg/cGg                                                           NM_001167882.1;NM_020337.2                                                                                             ANKRD50;ANKRD50                                                  Homo_ref   Heter
  chr4    1.55E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   F177L;F771L                                             Ttt/Ctt;Ttt/Ctt                                                           NM_017639.3;NM_001142552.1                                                                                             DCHS2;DCHS2                                                      Homo_ref   Heter
  chr4    1.56E+08   T            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   I187K                                                   aTa/aAa                                                                   NM_004744.3                                                                                                            LRAT                                                             Homo_ref   Heter
  chr4    1.56E+08   C            T              SPLICE_SITE_DONOR(HIGH)                                                                                                                                                                                                                                                                                                                                                                                                             NM_001039580.1                                                                                                         MAP9                                                             Homo_ref   Heter
  chr5    434878     G            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   G679R;G697R                                             Ggg/Agg;Ggg/Agg                                                           NM_001242412.1;NM_020731.4                                                                                             AHRR;AHRR                                                        Homo_ref   Heter
  chr5    23527585   GACACACACA   GACACACACACA   FRAME_SHIFT(HIGH)                                                                                                                                                                                                                                                                                 -800?                                                   -/CA                                                                      NM_020227.2                                                                                                            PRDM9                                                            Homo_ref   Heter
  chr5    31799521   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   T56S                                                    Acg/Tcg                                                                   NM_178140.2                                                                                                            PDZD2                                                            Homo_ref   Heter
  chr5    54624530   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Y136H                                                   Tac/Cac                                                                   NM_015360.4                                                                                                            SKIV2L2                                                          Homo_ref   Heter
  chr5    1.32E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                   I124T;I124T;I124T;I64T                                  aTc/aCc;aTc/aCc;aTc/aCc;aTc/aCc                                           NM_015146.1;NM_001098812.1;NM_001098811.1;NM_001098813.1                                                               SEPT8;SEPT8;SEPT8;SEPT8                                          Homo_ref   Heter
  chr5    1.4E+08    T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V60A;V60A                                               gTg/gCg;gTg/gCg                                                           NM_031500.1;NM_018907.2                                                                                                PCDHA4;PCDHA4                                                    Homo_ref   Heter
  chr5    1.4E+08    T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V552A;V552A                                             gTg/gCg;gTg/gCg                                                           NM_031501.1;NM_018908.2                                                                                                PCDHA5;PCDHA5                                                    Homo_ref   Heter
  chr5    1.41E+08   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   E38V                                                    gAa/gTa                                                                   NM_020957.1                                                                                                            PCDHB16                                                          Homo_ref   Heter
  chr5    1.79E+08   C            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D22H                                                    Gac/Cac                                                                   NM_001142306.1                                                                                                         C5orf60                                                          Homo_ref   Heter
  chr6    553900     G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S692F                                                   tCc/tTc                                                                   NM_018303.5                                                                                                            EXOC2                                                            Homo_ref   Heter
  chr6    25972305   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   G239D                                                   gGc/gAc                                                                   NM_006355.3                                                                                                            TRIM38                                                           Homo_ref   Heter
  chr6    39073484   G            T              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 C92\*                                                   tgC/tgA                                                                   NM_018322.1                                                                                                            SAYSD1                                                           Homo_ref   Heter
  chr6    43267448   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V194A;V196A                                             gTa/gCa;gTa/gCa                                                           NM_006672.3;NM_153320.2                                                                                                SLC22A7;SLC22A7                                                  Homo_ref   Heter
  chr6    1.61E+08   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   K2078I                                                  aAa/aTa                                                                   NM_000876.2                                                                                                            IGF2R                                                            Homo_ref   Heter
  chr6    1.71E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   W159R                                                   Tgg/Cgg                                                                   NM_005618.3                                                                                                            DLL1                                                             Homo_ref   Heter
  chr7    1538645    A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   V368A                                                   gTg/gCg                                                                   NM_001080453.2                                                                                                         INTS1                                                            Homo_ref   Heter
  chr7    48349667   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P3149S                                                  Cca/Tca                                                                   NM_152701.3                                                                                                            ABCA13                                                           Homo_ref   Heter
  chr7    91603099   A            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   K41N;K41N                                               aaA/aaC;aaA/aaC                                                           NM_147185.2;NM_005751.4                                                                                                AKAP9;AKAP9                                                      Homo_ref   Heter
  chr7    91756945   C            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V157F;V52F                                              Gtt/Ttt;Gtt/Ttt                                                           NM_000786.3;NM_001146152.1                                                                                             CYP51A1;CYP51A1                                                  Homo_ref   Heter
  chr7    97863036   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   T457A                                                   Acc/Gcc                                                                   NM_015395.2                                                                                                            TECPR1                                                           Homo_ref   Heter
  chr7    1E+08      T            TG             FRAME_SHIFT(HIGH);FRAME_SHIFT(HIGH)                                                                                                                                                                                                                                                               -1923?;-1923?                                           -/G;-/G                                                                   NM_173059.1;NM_003386.1                                                                                                ZAN;ZAN                                                          Homo_ref   Heter
  chr7    1.05E+08   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   V613G                                                   gTt/gGt                                                                   NM_019042.3                                                                                                            PUS7                                                             Homo_ref   Heter
  chr7    1.27E+08   C            A              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 E48\*                                                   Gag/Tag                                                                   NM_176814.3                                                                                                            ZNF800                                                           Homo_ref   Heter
  chr7    1.42E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R1437K                                                  aGg/aAg                                                                   NM_004668.2                                                                                                            MGAM                                                             Homo_ref   Heter
  chr7    1.49E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A66V                                                    gCc/gTc                                                                   NM_207336.1                                                                                                            ZNF467                                                           Homo_ref   Heter
  chr8    623772     C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D194N                                                   Gac/Aac                                                                   NM_207332.1                                                                                                            ERICH1                                                           Homo_ref   Heter
  chr8    35453086   T            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   F161V                                                   Ttt/Gtt                                                                   NM_080872.2                                                                                                            UNC5D                                                            Homo_ref   Heter
  chr8    1.42E+08   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R388C                                                   Cgc/Tgc                                                                   NM_001080431.1                                                                                                         SLC45A4                                                          Homo_ref   Heter
  chr8    1.45E+08   G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   M60I                                                    atG/atT                                                                   NM_001916.3                                                                                                            CYC1                                                             Homo_ref   Heter
  chr9    34255869   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   C1246R                                                  Tgc/Cgc                                                                   NM_194313.2                                                                                                            KIF24                                                            Homo_ref   Heter
  chr9    86452279   A            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   S1184R;S1215R;S1281R                                    agT/agA;agT/agA;agT/agA                                                   NM_001271928.1;NM_001271927.1;NM_017576.2                                                                              KIF27;KIF27;KIF27                                                Homo_ref   Heter
  chr9    96052320   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S1643P                                                  Tca/Cca                                                                   NM_006648.3                                                                                                            WNK2                                                             Homo_ref   Heter
  chr9    1.16E+08   T            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Q119P                                                   cAg/cCg                                                                   NM_015258.1                                                                                                            FKBP15                                                           Homo_ref   Heter
  chr9    1.25E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   K81R                                                    aAg/aGg                                                                   NM_001005235.1                                                                                                         OR1L4                                                            Homo_ref   Heter
  chr9    1.28E+08   C            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R438T                                                   aGa/aCa                                                                   NM_002077.3                                                                                                            GOLGA1                                                           Homo_ref   Heter
  chr9    1.34E+08   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   M114V                                                   Atg/Gtg                                                                   NM_021619.2                                                                                                            PRDM12                                                           Homo_ref   Heter
  chr9    1.34E+08   T            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S1441T                                                  Tcc/Acc                                                                   NM_006059.3                                                                                                            LAMC3                                                            Homo_ref   Heter
  chr9    1.37E+08   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Y189H                                                   Tac/Cac                                                                   NM_002957.4                                                                                                            RXRA                                                             Homo_ref   Heter
  chr9    1.39E+08   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   C58Y;C63Y                                               tGc/tAc;tGc/tAc                                                           NM_178138.4;NM_014564.3                                                                                                LHX3;LHX3                                                        Homo_ref   Heter
  chr10   17199504   G            A              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 R275\*                                                  Cga/Tga                                                                   NM_004412.5                                                                                                            TRDMT1                                                           Homo_ref   Heter
  chr10   26455049   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   T1018I                                                  aCc/aTc                                                                   NM_017433.4                                                                                                            MYO3A                                                            Homo_ref   Heter
  chr10   32304529   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   I940M                                                   atT/atG                                                                   NM_004521.2                                                                                                            KIF5B                                                            Homo_ref   Heter
  chr10   50819232   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   M149T                                                   aTg/aCg                                                                   NM_003055.2                                                                                                            SLC18A3                                                          Homo_ref   Heter
  chr10   98129916   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   V940D                                                   gTt/gAt                                                                   NM_012465.3                                                                                                            TLL2                                                             Homo_ref   Heter
  chr10   1.23E+08   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   V597A                                                   gTt/gCt                                                                   NM_018117.11                                                                                                           WDR11                                                            Homo_ref   Heter
  chr10   1.35E+08   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   K508R                                                   aAg/aGg                                                                   NM_001200049.2                                                                                                         TTC40                                                            Homo_ref   Heter
  chr11   612778     A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   V431A;V460A;V473A                                       gTg/gCg;gTg/gCg;gTg/gCg                                                   NM_004029.2;NM_001572.3;NM_004031.2                                                                                    IRF7;IRF7;IRF7                                                   Homo_ref   Heter
  chr11   773623     C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R85Q                                                    cGg/cAg                                                                   NM_182612.2                                                                                                            PDDC1                                                            Homo_ref   Heter
  chr11   1078307    G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   K198N                                                   aaG/aaT                                                                   NM_002457.2                                                                                                            MUC2                                                             Homo_ref   Heter
  chr11   2427314    A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   F1087L                                                  Ttc/Ctc                                                                   NM_014555.3                                                                                                            TRPM5                                                            Homo_ref   Heter
  chr11   66619985   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   T584A;T584A;T584A                                       Acc/Gcc;Acc/Gcc;Acc/Gcc                                                   NM_000920.3;NM_001040716.1;NM_022172.2                                                                                 PC;PC;PC                                                         Homo_ref   Heter
  chr11   77378107   G            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P1394R                                                  cCc/cGc                                                                   NM_016578.3                                                                                                            RSF1                                                             Homo_ref   Heter
  chr11   1.19E+08   C            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S662Y                                                   tCt/tAt                                                                   NM_021729.4                                                                                                            VPS11                                                            Homo_ref   Heter
  chr11   1.19E+08   A            T              STOP_GAINED(HIGH);STOP_GAINED(HIGH)                                                                                                                                                                                                                                                               K86\*;K86\*                                             Aag/Tag;Aag/Tag                                                           NM_001142505.1;NM_022169.4                                                                                             ABCG4;ABCG4                                                      Homo_ref   Heter
  chr12   6933276    C            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A71D                                                    gCc/gAc                                                                   NM_019858.1                                                                                                            GPR162                                                           Homo_ref   Heter
  chr12   9260161    C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   G280S                                                   Ggt/Agt                                                                   NM_000014.4                                                                                                            A2M                                                              Homo_ref   Heter
  chr12   53453359   G            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   R521L;R645L;R655L                                       cGa/cTa;cGa/cTa;cGa/cTa                                                   NM_198316.1;NM_170754.2;NM_015319.2                                                                                    TENC1;TENC1;TENC1                                                Homo_ref   Heter
  chr12   58197052   A            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   M647K                                                   aTg/aAg                                                                   NM_006576.3                                                                                                            AVIL                                                             Homo_ref   Heter
  chr12   69126435   G            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D673Y                                                   Gat/Tat                                                                   NM_020401.2                                                                                                            NUP107                                                           Homo_ref   Heter
  chr12   77235849   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P410L                                                   cCa/cTa                                                                   NM_015336.2                                                                                                            ZDHHC17                                                          Homo_ref   Heter
  chr13   39425170   C            T              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 Q2223\*                                                 Caa/Taa                                                                   NM_207361.4                                                                                                            FREM2                                                            Homo_ref   Heter
  chr14   73957946   T            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   L75R                                                    cTg/cGg                                                                   NM_024644.3                                                                                                            C14orf169                                                        Homo_ref   Heter
  chr14   1.04E+08   T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S218G                                                   Agt/Ggt                                                                   NM_015316.2                                                                                                            PPP1R13B                                                         Homo_ref   Heter
  chr15   66601046   G            T              SPLICE_SITE_ACCEPTOR(HIGH);SPLICE_SITE_ACCEPTOR(HIGH)                                                                                                                                                                                                                                             ;                                                       ;                                                                         NM_001143688.1;NM_133375.3                                                                                             DIS3L;DIS3L                                                      Homo_ref   Heter
  chr15   90801386   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R351H                                                   cGc/cAc                                                                   NM_001029964.2                                                                                                         TTLL13                                                           Homo_ref   Heter
  chr16   613451     T            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   Y53H                                                    Tac/Cac                                                                   NM_145270.2                                                                                                            C16orf11                                                         Homo_ref   Heter
  chr16   31230697   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   R192C                                                   Cgc/Tgc                                                                   NM_001008274.3                                                                                                         TRIM72                                                           Homo_ref   Heter
  chr17   4167225    A            G              SPLICE_SITE_DONOR(HIGH);SPLICE_SITE_DONOR(HIGH)                                                                                                                                                                                                                                                   ;                                                       ;                                                                         NM_016376.3;NR_047571.1                                                                                                ANKFY1;ANKFY1                                                    Homo_ref   Heter
  chr17   8045692    G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A1115V                                                  gCt/gTt                                                                   NM_002616.2                                                                                                            PER1                                                             Homo_ref   Heter
  chr17   37565110   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   S1122P                                                  Tca/Cca                                                                   NM_004774.3                                                                                                            MED1                                                             Homo_ref   Heter
  chr17   62856060   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   F1402L                                                  Ttt/Ctt                                                                   NM_199340.2                                                                                                            LRRC37A3                                                         Homo_ref   Heter
  chr17   73499968   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   Y433H;Y515H                                             Tat/Cat;Tat/Cat                                                           NM_001142643.1;NM_020753.3                                                                                             CASKIN2;CASKIN2                                                  Homo_ref   Heter
  chr17   76449531   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   E3475K                                                  Gag/Aag                                                                   NM_173628.3                                                                                                            DNAH17                                                           Homo_ref   Heter
  chr17   79555984   C            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D423Y                                                   Gat/Tat                                                                   NM_017921.2                                                                                                            NPLOC4                                                           Homo_ref   Heter
  chr18   3272991    A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   Q32R;Q32R;Q32R                                          cAg/cGg;cAg/cGg;cAg/cGg                                                   NM_001144944.1;NM_001144945.1;NM_033546.3                                                                              MYL12B;MYL12B;MYL12B                                             Homo_ref   Heter
  chr18   29867458   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   V368M;V368M                                             Gtg/Atg;Gtg/Atg                                                           NM_022751.2;NM_001242409.1                                                                                             GAREM;GAREM                                                      Homo_ref   Heter
  chr19   1295566    G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   D55N                                                    Gac/Aac                                                                   NM_001405.3                                                                                                            EFNA2                                                            Homo_ref   Heter
  chr19   9059365    C            A              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 E9361\*                                                 Gaa/Taa                                                                   NM_024690.2                                                                                                            MUC16                                                            Homo_ref   Heter
  chr19   16982170   CTT          CTTT           FRAME_SHIFT(HIGH)                                                                                                                                                                                                                                                                                 -884?                                                   -/T                                                                       NM_015260.2                                                                                                            SIN3B                                                            Homo_ref   Heter
  chr19   19414563   A            G              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   M211T                                                   aTg/aCg                                                                   NM_172231.3                                                                                                            SUGP1                                                            Homo_ref   Heter
  chr19   48305970   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P100S                                                   Cct/Tct                                                                   NM_198479.2                                                                                                            TPRX1                                                            Homo_ref   Heter
  chr19   48922916   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P646S                                                   Ccc/Tcc                                                                   NM_000836.2                                                                                                            GRIN2D                                                           Homo_ref   Heter
  chr19   49377522   T            G              STOP_GAINED(HIGH)                                                                                                                                                                                                                                                                                 Y344\*                                                  taT/taG                                                                   NM_014330.3                                                                                                            PPP1R15A                                                         Homo_ref   Heter
  chr19   54759960   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   K201E;K201E                                             Aaa/Gaa;Aaa/Gaa                                                           NM_006840.3;NM_001081442.1                                                                                             LILRB5;LILRB5                                                    Homo_ref   Heter
  chr19   56185411   T            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   Y465N;Y469N                                             Tat/Aat;Tat/Aat                                                           NM_001012478.1;NM_007279.2                                                                                             U2AF2;U2AF2                                                      Homo_ref   Heter
  chr19   57325702   C            T              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                   A1244T;A1246T;A1370T;A1370T;A1370T                      Gca/Aca;Gca/Aca;Gca/Aca;Gca/Aca;Gca/Aca                                   NM_001146185.1;NM_001146187.1;NM_001146184.1;NM_001146186.1;NM_006210.2                                                PEG3;PEG3;PEG3;PEG3;PEG3                                         Homo_ref   Heter
  chr19   57640078   T            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   I12N                                                    aTt/aAt                                                                   NM_020903.2                                                                                                            USP29                                                            Homo_ref   Heter
  chr20   17928162   T            A              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   K349I;K349I                                             aAa/aTa;aAa/aTa                                                           NM_014426.2;NM_152227.1                                                                                                SNX5;SNX5                                                        Homo_ref   Heter
  chr20   31656753   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P375S                                                   Cct/Tct                                                                   NM_182658.1                                                                                                            BPIFB3                                                           Homo_ref   Heter
  chr20   43052973   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   L381P;L403P                                             cTc/cCc;cTc/cCc                                                           NM_001030004.2;NM_178850.2                                                                                             HNF4A;HNF4A                                                      Homo_ref   Heter
  chr20   48808388   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   E273A                                                   gAg/gCg                                                                   NM_005194.3                                                                                                            CEBPB                                                            Homo_ref   Heter
  chr20   50342443   A            C              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   F81C                                                    tTc/tGc                                                                   NM_006045.1                                                                                                            ATP9A                                                            Homo_ref   Heter
  chr20   54970702   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   N32D;N32D;N32D                                          Aat/Gat;Aat/Gat;Aat/Gat                                                   NM_001033521.1;NM_001033522.1;NM_001324.2                                                                              CSTF1;CSTF1;CSTF1                                                Homo_ref   Heter
  chr21   41559073   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   C922R;C922R                                             Tgc/Cgc;Tgc/Cgc                                                           NM_001271534.1;NM_001389.3                                                                                             DSCAM;DSCAM                                                      Homo_ref   Heter
  chr21   43867183   T            C              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                   C512R;M584T;M622T                                       Tgt/Cgt;aTg/aCg;aTg/aCg                                                   NM_001243467.1;NM_001001895.2;NM_018961.3                                                                              UBASH3A;UBASH3A;UBASH3A                                          Homo_ref   Heter
  chr21   45994548   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   P305S                                                   Cca/Tca                                                                   NM_198687.1                                                                                                            KRTAP10-4                                                        Homo_ref   Heter
  chr21   46086757   G            A              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A16V                                                    gCg/gTg                                                                   NM_181684.2                                                                                                            KRTAP12-2                                                        Homo_ref   Heter
  chr21   46086758   C            T              NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                                                   A16T                                                    Gcg/Acg                                                                   NM_181684.2                                                                                                            KRTAP12-2                                                        Homo_ref   Heter
  chr22   23596000   A            G              NON_SYNONYMOUS_CODING(MODERATE);NON_SYNONYMOUS_CODING(MODERATE)                                                                                                                                                                                                                                   T432A;T432A                                             Aca/Gca;Aca/Gca                                                           NM_021574.2;NM_004327.3                                                                                                BCR;BCR                                                          Homo_ref   Heter
  chr3    15613277   CTTAA        C              SPLICE_SITE_ACCEPTOR(HIGH)                                                                                                                                                                                                                                                                                                                                                                                                          NM_012260.2                                                                                                            HACL1                                                            Heter      Homo_ALT

###### Relative expression of ERBB1-4, seven EGFR ligands, and MET in CC and CC-CR

  Gene Name   FPKM[1](#TFN1){ref-type="table-fn"} CC 1   FPKM CC 2   FPKM CC 3   FPKM CC-CR 1   FPKM CC-CR 2   FPKM CC-CR 3   Log~2~FC[2](#TFN2){ref-type="table-fn"} (CC-CR vs CC)   FDR
  ----------- ------------------------------------------ ----------- ----------- -------------- -------------- -------------- ------------------------------------------------------- ----------
  EGFR        7.113792                                   7.216315    6.9096      10.53567       8.838911       9.740446       0.457468                                                6.32E-06
  ERBB2       24.23383                                   24.52192    23.97762    23.07252       25.54938       21.22859       -0.05656                                                0.730888
  ERBB3       18.79607                                   18.91252    17.90869    19.07041       20.00568       14.89755       -0.04198                                                0.859801
  ERBB4       0                                          0.005107    0           0.016069       0              0.004937       NA                                                      NA
  AREG        21.5716                                    21.76646    20.76116    13.48585       13.73754       17.10571       -0.5276                                                 0.000618
  BTC         6.413408                                   5.307637    6.723783    5.5914         5.375864       8.232057       0.062581                                                0.881371
  EGF         0.568842                                   0.769771    0.574685    0.488951       0.322759       0.366821       -0.69627                                                0.012365
  EPGN        0.139733                                   0.109859    0.183119    0              0.263141       0.176997       NA                                                      NA
  EREG        31.82304                                   31.86035    37.40712    21.31407       23.27111       33.68543       -0.36529                                                0.117939
  HBEGF       3.170548                                   2.707305    2.575539    3.416546       3.66036        3.297967       0.295692                                                0.175018
  TGFA        13.67483                                   12.79573    11.80663    19.20377       16.29553       15.21587       0.407307                                                0.000454
  MET         135.2686                                   157.1884    149.2257    213.2824       228.8418       221.7658       0.590334                                                3.12E-09

FPKM stands for Fragments Per Kilobase of transcript per Million mapped reads.

Differential expression analysis was performed on RNA-Seq counts using edgeR.

###### 

Mutational status of 30 CRC cell lines used in [Fig. 2f](#F13){ref-type="fig"} and their response to cetuximab

  Cell line   Mutational status   Mean CTX inhibition rate (%)           CTX response category
  ----------- ------------------- -------------------------------------- -----------------------
  NCI-H508    *BRAF*              83.4[1](#TFN3){ref-type="table-fn"}    sensitive
  V9P         WT                  82.0[3](#TFN5){ref-type="table-fn"}    sensitive
  DiFi        WT                  80.8[1](#TFN3){ref-type="table-fn"}    sensitive
  LIM1215     WT                  79.6[2](#TFN4){ref-type="table-fn"}    sensitive
  GEO         *KRAS*              68.7[2](#TFN4){ref-type="table-fn"}    sensitive
  SW403       *KRAS*              66.0[2](#TFN4){ref-type="table-fn"}    sensitive
  SNUC4       WT                  48.3[1](#TFN3){ref-type="table-fn"}    partially responsive
  Caco-2      WT                  47.7[2](#TFN4){ref-type="table-fn"}    partially responsive
  SW948       *KRAS*              42.7[2](#TFN4){ref-type="table-fn"}    partially responsive
  HT29        *BRAF*              36.5[2](#TFN4){ref-type="table-fn"}    partially responsive
  SK-CO-1     *KRAS*              33.9[2](#TFN4){ref-type="table-fn"}    partially responsive
  DLD-1       *KRAS*              24.9[2](#TFN4){ref-type="table-fn"}    resistant
  SW480       *KRAS*              23.7[2](#TFN4){ref-type="table-fn"}    resistant
  SW837       *KRAS*              21.8[2](#TFN4){ref-type="table-fn"}    resistant
  SW48        WT                  21.8[2](#TFN4){ref-type="table-fn"}    resistant
  SW620       *KRAS*              14.5[2](#TFN4){ref-type="table-fn"}    resistant
  LoVo        *KRAS*              14.3[1](#TFN3){ref-type="table-fn"}    resistant
  COLO205     *BRAF*              12.5[1](#TFN3){ref-type="table-fn"}    resistant
  T84         *KRAS*              11.2[2](#TFN4){ref-type="table-fn"}    resistant
  LS174T      *KRAS*              9.7[1](#TFN3){ref-type="table-fn"}     resistant
  NCI-H716    WT                  9.7[1](#TFN3){ref-type="table-fn"}     resistant
  HCT8        *KRAS*              8.4[1](#TFN3){ref-type="table-fn"}     resistant
  HCT15       *KRAS*              4.5[2](#TFN4){ref-type="table-fn"}     resistant
  SW1116      *KRAS*              2.0[1](#TFN3){ref-type="table-fn"}     resistant
  LIM2405     *KRAS*              2.0[2](#TFN4){ref-type="table-fn"}     resistant
  RKO         *BRAF*              0.4[1](#TFN3){ref-type="table-fn"}     resistant
  COLO320DM   WT                  -3.2[1](#TFN3){ref-type="table-fn"}    resistant
  HuTu80      WT                  -5.4[1](#TFN3){ref-type="table-fn"}    resistant
  LS123       *KRAS*              -4.8[1](#TFN3){ref-type="table-fn"}    resistant
  HCT116      *KRAS*              -14.1[2](#TFN4){ref-type="table-fn"}   resistant

Data came from Medico, E. *et al*, *Nat Commun*, 2015^[@R17]^.

Data came from Jhawer, M. *et al*, *Cancer Res*, 2008^[@R16]^.

Experimental data from the present study.

  miRNA             PathName                                                     PathFg   PathBg   GenomeFG   GenomeBG   pval         BH
  ----------------- ------------------------------------------------------------ -------- -------- ---------- ---------- ------------ ------------
  hsa-miR-100-5p    Pathways in cancer                                           197      330      8828       19747      2.49E-08     4.84E-06
  hsa-miR-100-5p    Pancreatic cancer                                            52       75       8828       19747      1.39E-05     0.00264553
  hsa-miR-100-5p    Wnt signaling pathway                                        94       152      8828       19747      1.49E-05     0.00285334
  hsa-miR-100-5p    mTOR signaling pathway                                       39       53       8828       19747      1.87E-05     0.00354634
  hsa-miR-100-5p    Ubiquitin mediated proteolysis                               83       134      8828       19747      4.24E-05     0.00797254
  hsa-miR-100-5p    Glioma                                                       45       65       8828       19747      5.51E-05     0.01025001
  hsa-miR-100-5p    Endocytosis                                                  110      187      8828       19747      6.79E-05     0.0124941
  hsa-miR-100-5p    Chronic myeloid leukemia                                     50       75       8828       19747      0.00010082   0.01834838
  hsa-miR-100-5p    Calcium signaling pathway                                    104      178      8828       19747      0.00015222   0.02739988
  hsa-miR-100-5p    Focal adhesion                                               116      203      8828       19747      0.00023268   0.04141736
  hsa-miR-100-5p    Leukocyte transendothelial migration                         71       116      8828       19747      0.00024812   0.04416472
  hsa-miR-100-5p    Insulin signaling pathway                                    83       139      8828       19747      0.00025507   0.04514807
  hsa-miR-100-5p    Non small cell lung cancer                                   37       54       8828       19747      0.00034689   0.06035915
  hsa-miR-100-5p    Apoptosis                                                    55       87       8828       19747      0.00038021   0.06577642
  hsa-miR-100-5p    MAPK signaling pathway                                       149      272      8828       19747      0.0004966    0.0849182
  hsa-miR-100-5p    Renal cell carcinoma                                         46       71       8828       19747      0.00050651   0.08661247
  hsa-miR-100-5p    Long term potentiation                                       46       71       8828       19747      0.00050651   0.08661247
  hsa-miR-100-5p    Axon guidance                                                76       129      8828       19747      0.00079389   0.13257995
  hsa-miR-100-5p    Small cell lung cancer                                       52       84       8828       19747      0.00110523   0.17904734
  hsa-miR-100-5p    Colorectal cancer                                            53       86       8828       19747      0.00115401   0.18694947
  hsa-miR-100-5p    Aldosterone regulated sodium reabsorption                    29       42       8828       19747      0.00124064   0.19974264
  hsa-miR-100-5p    Phosphatidylinositol signaling system                        47       76       8828       19747      0.00193595   0.30200877
  hsa-miR-100-5p    Chondroitin sulfate biosynthesis                             17       22       8828       19747      0.00195406   0.30483395
  hsa-miR-100-5p    VEGF signaling pathway                                       48       78       8828       19747      0.00201937   0.31502171
  hsa-miR-100-5p    Hedgehog signaling pathway                                   36       56       8828       19747      0.0024547    0.37556932
  hsa-miR-100-5p    Cell adhesion molecules CAMs                                 76       133      8828       19747      0.0025693    0.39310273
  hsa-miR-100-5p    Vascular smooth muscle contraction                           67       116      8828       19747      0.0031307    0.47273626
  hsa-miR-100-5p    Glycosphingolipid biosynthesis lacto and neolacto series     19       26       8828       19747      0.00320356   0.48373791
  hsa-miR-100-5p    Amyotrophic lateral sclerosis ALS                            35       55       8828       19747      0.00359894   0.53624172
  hsa-miR-100-5p    Fc gamma R mediated phagocytosis                             57       97       8828       19747      0.00366845   0.54659853
  hsa-miR-100-5p    Lysosome                                                     69       121      8828       19747      0.0042201    0.61613498
  hsa-miR-100-5p    Dilated cardiomyopathy                                       55       94       8828       19747      0.00484392   0.6975252
  hsa-miR-100-5p    Melanoma                                                     43       71       8828       19747      0.00514181   0.73527865
  hsa-miR-100-5p    Heparan sulfate biosynthesis                                 18       26       8828       19747      0.01012535   1
  hsa-miR-100-5p    Lysine degradation                                           28       45       8828       19747      0.01350559   1
  hsa-miR-100-5p    Melanogenesis                                                57       102      8828       19747      0.01500276   1
  hsa-miR-100-5p    GnRH signaling pathway                                       56       105      8828       19747      0.04641394   1
  hsa-miR-100-5p    Arrhythmogenic right ventricular cardiomyopathy ARVC         41       74       8828       19747      0.04152065   1
  hsa-miR-100-5p    Keratan sulfate biosynthesis                                 11       15       8828       19747      0.02407578   1
  hsa-miR-100-5p    Regulation of actin cytoskeleton                             110      212      8828       19747      0.02068052   1
  hsa-miR-100-5p    Type II diabetes mellitus                                    29       49       8828       19747      0.02922526   1
  hsa-miR-100-5p    Neurotrophin signaling pathway                               70       129      8828       19747      0.0180486    1
  hsa-miR-100-5p    O Glycan biosynthesis                                        20       30       8828       19747      0.01266537   1
  hsa-miR-100-5p    Valine leucine and isoleucine degradation                    28       45       8828       19747      0.01350559   1
  hsa-miR-100-5p    Adherens junction                                            45       76       8828       19747      0.0076372    1
  hsa-miR-100-5p    ABC transporters                                             26       44       8828       19747      0.03875465   1
  hsa-miR-100-5p    Basal cell carcinoma                                         34       55       8828       19747      0.00786933   1
  hsa-miR-100-5p    Prostate cancer                                              48       89       8828       19747      0.05007106   1
  hsa-miR-100-5p    TGF beta signaling pathway                                   47       86       8828       19747      0.04039675   1
  hsa-miR-100-5p    Dorso ventral axis formation                                 16       24       8828       19747      0.02509059   1
  hsa-miR-100-5p    Nicotinate and nicotinamide metabolism                       17       24       8828       19747      0.0087657    1
  hsa-miR-100-5p    Adipocytokine signaling pathway                              41       70       8828       19747      0.01352383   1
  hsa-miR-100-5p    Fc epsilon RI signaling pathway                              46       82       8828       19747      0.0248563    1
  hsa-miR-100-5p    Butanoate metabolism                                         21       35       8828       19747      0.04970063   1
  hsa-miR-100-5p    Notch signaling pathway                                      28       47       8828       19747      0.02864452   1
  hsa-miR-100-5p    T cell receptor signaling pathway                            58       110      8828       19747      0.05508698   1
  hsa-miR-100-5p    p53 signaling pathway                                        40       68       8828       19747      0.01330284   1
  hsa-miR-100-5p    ErbB signaling pathway                                       51       89       8828       19747      0.0112398    1
  hsa-miR-100-5p    Hypertrophic cardiomyopathy HCM                              49       86       8828       19747      0.01467435   1
  miRNA             PathName                                                     PathFg   PathBg   GenomeFG   GenomeBG   pval         BH
  hsa-miR-125b-5p   MAPK signaling pathway                                       217      272      12145      19747      5.52E-11     1.07E-08
  hsa-miR-125b-5p   Axon guidance                                                108      129      12145      19747      3.01E-08     5.77E-06
  hsa-miR-125b-5p   Pathways in cancer                                           249      330      12145      19747      4.35E-08     8.35E-06
  hsa-miR-125b-5p   Regulation of actin cytoskeleton                             165      212      12145      19747      2.56E-07     4.84E-05
  hsa-miR-125b-5p   Insulin signaling pathway                                    113      139      12145      19747      3.55E-07     6.71E-05
  hsa-miR-125b-5p   Glioma                                                       58       65       12145      19747      5.88E-07     0.0001106
  hsa-miR-125b-5p   Cell adhesion molecules CAMs                                 108      133      12145      19747      7.17E-07     0.00013411
  hsa-miR-125b-5p   Wnt signaling pathway                                        121      152      12145      19474      1.1E-06      0.00022601
  hsa-miR-125b-5p   ErbB signaling pathway                                       74       89       12145      19747      7.66E-06     0.0014179
  hsa-miR-125b-5p   Hedgehog signaling pathway                                   49       56       12145      19747      1.64E-05     0.00298105
  hsa-miR-125b-5p   Endocytosis                                                  142      187      12145      19747      1.87E-05     0.00339254
  hsa-miR-125b-5p   Neurotrophin signaling pathway                               101      129      12145      19747      3.36E-05     0.00602008
  hsa-miR-125b-5p   Chronic myeloid leukemia                                     62       75       12145      19747      6.00E-05     0.01061902
  hsa-miR-125b-5p   Pancreatic cancer                                            62       75       12145      19747      6.00E-05     0.01061902
  hsa-miR-125b-5p   Melanoma                                                     59       71       12145      19747      6.69E-05     0.01177116
  hsa-miR-125b-5p   Focal adhesion                                               151      203      12145      19747      6.80E-05     0.01196783
  hsa-miR-125b-5p   Notch signaling pathway                                      41       47       12145      19747      9.72E-05     0.0170169
  hsa-miR-125b-5p   Non small cell lung cancer                                   46       54       12145      19747      0.0001296    0.02255083
  hsa-miR-125b-5p   Leukocyte transendothelial migration                         90       116      12145      19747      0.00016225   0.02774454
  hsa-miR-125b-5p   Long term potentiation                                       58       71       12145      19747      0.00019926   0.03367434
  hsa-miR-125b-5p   Colorectal cancer                                            68       86       12145      19747      0.00037718   0.06185754
  hsa-miR-125b-5p   Calcium signaling pathway                                    131      178      12145      19747      0.00043597   0.07106345
  hsa-miR-125b-5p   Glycosphingolipid biosynthesis lacto and neolacto series     24       26       12145      19747      0.00046625   0.07596159
  hsa-miR-125b-5p   mTOR signaling pathway                                       44       53       12145      19747      0.00059905   0.09644727
  hsa-miR-125b-5p   Endometrial cancer                                           43       52       12145      19747      0.00081681   0.12905666
  hsa-miR-125b-5p   Phosphatidylinositol signaling system                        60       76       12145      19747      0.00088761   0.14024252
  hsa-miR-125b-5p   Prostate cancer                                              69       89       12145      19747      0.00095427   0.14982021
  hsa-miR-125b-5p   VEGF signaling pathway                                       61       78       12145      19747      0.00125492   0.19576823
  hsa-miR-125b-5p   T cell receptor signaling pathway                            83       110      12145      19747      0.0013653    0.21298668
  hsa-miR-125b-5p   Vascular smooth muscle contraction                           87       116      12145      19747      0.00146085   0.22643156
  hsa-miR-125b-5p   Lysosome                                                     90       121      12145      19747      0.00189772   0.28891677
  hsa-miR-125b-5p   Long term depression                                         57       73       12145      19747      0.00192366   0.29239561
  hsa-miR-125b-5p   Melanogenesis                                                77       102      12145      19747      0.00196211   0.29824123
  hsa-miR-125b-5p   GnRH signaling pathway                                       79       105      12145      19747      0.00203279   0.30695151
  hsa-miR-125b-5p   Adherens junction                                            59       76       12145      19747      0.00207114   0.31274149
  hsa-miR-125b-5p   Basal cell carcinoma                                         44       55       12145      19747      0.00265051   0.38962493
  hsa-miR-125b-5p   Renal cell carcinoma                                         55       71       12145      19747      0.00316848   0.45635002
  hsa-miR-125b-5p   Apoptosis                                                    66       87       12145      19747      0.00326215   0.46975023
  hsa-miR-125b-5p   Chemokine signaling pathway                                  134      189      12145      19747      0.00422669   0.59596343
  hsa-miR-125b-5p   Fc epsilon RI signaling pathway                              62       82       12145      19747      0.00490539   0.68675477
  hsa-miR-125b-5p   Type II diabetes mellitus                                    39       49       12145      19747      0.00543661   0.75568815
  hsa-miR-125b-5p   Fc gamma R mediated phagocytosis                             72       97       12145      19747      0.00565361   0.78585178
  hsa-miR-125b-5p   Arrhythmogenic right ventricular cardiomyopathy ARVC         56       74       12145      19747      0.00711268   0.98155051
  hsa-miR-125b-5p   Epithelial cell signaling in Helicobacter pylori infection   52       71       12145      19747      0.0257727    1
  hsa-miR-125b-5p   Chondroitin sulfate biosynthesis                             18       22       12145      19747      0.03634967   1
  hsa-miR-125b-5p   SNARE interactions in vesicular transport                    30       39       12145      19747      0.03157198   1
  hsa-miR-125b-5p   Glycerophospholipid metabolism                               51       70       12145      19747      0.03130765   1
  hsa-miR-125b-5p   O Glycan biosynthesis                                        25       30       12145      19747      0.00882287   1
  hsa-miR-125b-5p   TGF beta signaling pathway                                   62       86       12145      19747      0.02614341   1
  hsa-miR-125b-5p   p53 signaling pathway                                        50       68       12145      19747      0.02553146   1
  hsa-miR-125b-5p   Hypertrophic cardiomyopathy HCM                              62       86       12145      19747      0.02614341   1
  hsa-miR-125b-5p   Gap junction                                                 64       90       12145      19747      0.03662525   1
  hsa-miR-125b-5p   Ubiquitin mediated proteolysis                               95       134      12145      19747      0.01448207   1
  hsa-miR-125b-5p   Inositol phosphate metabolism                                41       54       12145      19747      0.01834602   1
  hsa-miR-125b-5p   Keratan sulfate biosynthesis                                 13       15       12145      19747      0.03506366   1
  hsa-miR-125b-5p   Acute myeloid leukemia                                       43       58       12145      19747      0.03011936   1
  hsa-miR-125b-5p   B cell receptor signaling pathway                            54       75       12145      19747      0.0377669    1
  hsa-miR-125b-5p   Tight junction                                               94       132      12145      19747      0.01241454   1
  hsa-miR-125b-5p   Bladder cancer                                               33       43       12145      19747      0.02592105   1
  hsa-miR-125b-5p   Vibrio cholerae infection                                    40       55       12145      19747      0.05536572   1
  hsa-miR-125b-5p   Small cell lung cancer                                       61       84       12145      19747      0.02174543   1
  hsa-miR-125b-5p   Adipocytokine signaling pathway                              52       70       12145      19747      0.0169451    1
  hsa-miR-125b-5p   Dilated cardiomyopathy                                       66       94       12145      19747      0.04946503   1

###### Schema of miR-100 and/or miR-125b binding sites in predicted target 3′ UTR sequences of human genes

  Gene    Target Site[1](#TFN6){ref-type="table-fn"}   3′ UTR Position
  ------- -------------------------------------------- -----------------
  DKK1                                                 88-98
  DKK1                                                 422-421
  DKK3                                                 641-647
  ZNRF3                                                1164-1172
  ZNRF3                                                475-481
  ZNRF3                                                1529-1535
  RNF43                                                1308-1314
  RNF43                                                1462-1468
  APC2                                                 625-631
  APC2                                                 1612-1618
  GATA6                                                851-857

Putative binding sites of miR-100 or miR-125b were mutated and highlighted in red.

###### Predicted transcription factors for MIR100HG

  Feature           Name[1](#TFN7){ref-type="table-fn"}   logFC[2](#TFN8){ref-type="table-fn"}   logCPM    LR         *p*-Value   FDR
  ----------------- ------------------------------------- -------------------------------------- --------- ---------- ----------- --------
  ENSG00000141448   GATA6                                 -5.4301                                3.5893    538.9645   0.0000      0.0000
  ENSG00000156127   BATF                                  -4.9970                                -0.5743   32.7572    0.0000      0.0000
  ENSG00000089225   TBX5                                  -4.7068                                -0.6593   31.4959    0.0000      0.0000
  ENSG00000054598   FOXC1                                 -1.2082                                3.0427    42.6754    0.0000      0.0000
  ENSG00000007372   PAX6                                  -0.8470                                2.0843    21.5947    0.0000      0.0001
  ENSG00000160973   FOXH1                                 -0.7994                                0.8274    6.3042     0.0120      0.0741
  ENSG00000114315   HES1                                  -0.7992                                1.4362    10.5755    0.0011      0.0124
  ENSG00000150907   FOXO1                                 0.6164                                 4.8378    32.5211    0.0000      0.0000
  ENSG00000185630   PBX1                                  0.6217                                 5.3528    27.5587    0.0000      0.0000
  ENSG00000132170   PPARG                                 0.6402                                 5.5378    23.0551    0.0000      0.0000
  ENSG00000139515   PDX1                                  0.6714                                 0.1886    2.6065     0.1064      0.3237
  ENSG00000134954   ETS1                                  0.7010                                 4.8578    20.7411    0.0000      0.0001
  ENSG00000182759   MAFA                                  0.7297                                 1.1876    9.7487     0.0018      0.0177
  ENSG00000138378   STAT4                                 0.7530                                 1.0413    5.5393     0.0186      0.1010
  ENSG00000113916   BCL6                                  0.7550                                 5.5013    25.0300    0.0000      0.0000
  ENSG00000115415   STAT1                                 0.7756                                 7.6784    45.7658    0.0000      0.0000
  ENSG00000179388   EGR3                                  1.1668                                 1.8093    29.3749    0.0000      0.0000
  ENSG00000179348   GATA2                                 1.1681                                 5.7637    24.0412    0.0000      0.0000
  ENSG00000165556   CDX2                                  3.1288                                 5.0992    71.7325    0.0000      0.0000

Possible transcription factor binding sites within the 2.5 kb promoter region of MIR100HG were predicted by the Match program (version 1.0).

Candidate transcription factors differentially expressed between CC and CC-CR (fold change \>1.5) were listed.

###### Clinic-pathological characteristics of metastatic CRC patients with paired specimen pre- and post-cetuximab treatment

  No.[1](#TFN9){ref-type="table-fn"}   Gender   Age   Primary site       Metastatic sites                 Differentiation[2](#TFN10){ref-type="table-fn"}   Cetuximab regimen[3](#TFN11){ref-type="table-fn"}   Best response to cetuximab[4](#TFN12){ref-type="table-fn"}   Site of specimen (pre)     Site of specimen (post)
  ------------------------------------ -------- ----- ------------------ -------------------------------- ------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------ -------------------------- -------------------------
  1                                    M        56    left colon         lung, liver, peritoneal cavity   G2                                                FOLFOX4+cetuximab                                   PR                                                           sigmoid                    liver lesion
  2                                    F        39    left colon         left ovary and adnexa, lung      G1                                                FOLFIRI+cetuximab                                   SD                                                           sigmoid                    left adnexal mass
  3                                    M        52    right colon        lung, liver, peritoneal cavity   G1-G2                                             FOLFIRI+cetuximab                                   SD                                                           Hepatic flexure of colon   abdominal wall mass
  4                                    M        52    left colon         liver                            G2-G3                                             FOLFIRI+cetuximab                                   SD                                                           left colon                 liver lesion
  5                                    F        55    left colon         liver                            G1                                                FOLFOX4+cetuximab                                   PR                                                           sigmoid                    liver lesion
  6                                    M        55    rectosigmoid       liver                            G2                                                FOLFOX4+cetuximab                                   PR                                                           rectum                     rectum
  7                                    F        48    left colon         lung, liver, peritoneal cavity   G2                                                mFOLFOX6+cetuximab                                  SD                                                           sigmoid                    omental mass
  8                                    F        81    transverse colon   liver, bone                      G3                                                Cetuximab alone                                     SD                                                           transverse colon           transverse colon
  9                                    M        57    left colon         liver and lung                   G2                                                FOLFOX4+cetuximab                                   PR                                                           sigmoid                    sigmoid
  10                                   M        72    rectum             liver                            G2                                                FOLFOX4+cetuximab                                   PR                                                           rectum                     liver lesion

Cases 1, 2, 3 in [Fig. 6d](#F17){ref-type="fig"} denote subject No. 2, 3, 5 in this table.

G1, well-differentiated, G2, moderately differentiated, G3, poorly differentiated.

Cetuximab 400 mg/m^2^ initial dose followed by 250 mg/m^2^ weekly thereafter with cetuximab dose intensity\>90% were given to all subjects. Chemotherapy regimens: FOLFOX4 or mFOLFOX6, modified FOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin).

PR, Partial Response; SD, Stable Disease.

###### 

*KRAS, NRAS*, and *BRAF* mutational status and *MET* amplification status in CRC patients with paired specimens obtained prior to cetuximab (Pre) and at time of tumor progression (Post)

  No.[1](#TFN13){ref-type="table-fn"}   Combined analysis of *KRAS, NRAS*, and *BRAF*[2](#TFN14){ref-type="table-fn"}   *MET/CEP7* ratio[3](#TFN15){ref-type="table-fn"}   miR-100/125b expression change (Post vs Pre)         
  ------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------- ---------------------------------------------- ----- ------
  1                                     WT                                                                              WT                                                 \<2                                            \<2   Up
  2                                     WT                                                                              *NRAS* c.182A\>T p.Q61L                            \<2                                            \<2   Up
  3                                     WT                                                                              WT                                                 n.d.                                           \<2   Up
  4                                     WT                                                                              *KRAS* c.34G\>A p.G12S                             \<2                                            \<2   Up
  5                                     WT                                                                              WT                                                 \<2                                            \<2   Up
  6                                     WT                                                                              WT                                                 \<2                                            \<2   Down
  7                                     WT                                                                              WT                                                 \<2                                            \<2   Down
  8                                     WT                                                                              WT                                                 n.d.                                           \<2   Up
  9                                     WT                                                                              WT                                                 \<2                                            \<2   Down
  10                                    WT                                                                              WT                                                 n.d.                                           \<2   Up

Cases 1, 2, 3 in [Fig. 6d](#F17){ref-type="fig"} denote Subjects No. 2, 3, 5 in this table.

*NRAS* Q61L and *KRAS* G12S were identified in post-treatment specimens of Subject No. 2 and 4, respectively. In these two cases, DNA isolated from both the pre-and post-treatment samples was sequenced in parallel for *KRAS*, *NRAS*, and *BRAF*.

WT, wild-type; n.d., not detected.

###### Primers used in the qRT-PCR assays for indicated genes

  Gene Name   Forward Primer Sequence (5′ to 3′)   Reverse Primer Sequence (5′ to 3′)
  ----------- ------------------------------------ ------------------------------------
  ACTB        GGACTTCGAGCAAGAGATGG                 AGCACTGTGTTGGCGTACAG
  DKK1        AACAGCTATCCAAATGCAG                  TCACAGGGGAGTTCCATAAA
  DKK3        CTGGGAGCTAGAGCCTGATG                 TCATACTCATCGGGGACCTC
  CCND1       TTCAAATGTGTGCAGAAGGA                 GGGATGGTCTCCTTCATCTT
  KLF4        CGAACCCACACAGGTGAGAA                 TACGGTAGTGCCTGGTCAGTTC
  MYC         ACCAGAGAAACCTAACAGTGC                CTCTTTCATTTCGGCCAGTTC
  NKD1        TGCCTCCTGAGAAGACTGAC                 CATAGATGGTGTGCAGCAAG
  PROX1       TCACCTTATTCGGGAAGTGC                 GTACTGGTGACCCCATCGTT
  S100A4      AACTAAAGGAGCTGCTGACCC                TGTTGCTGTCCAAGTTGCTC
  CD44        TAGGAGAAGGTGTGGGCAGAA                GAGCTCACTGGGTTTCCTGTCTT
  FOSL1       AGTCAGGAGCTGCAGTGGATGGT              TCAGTTCCTTCCTCCGGTTCCTGC
  GATA6       TGCAATGCTTGTGGACTCTA                 GTGGGGGAAGTATTTTTGCT
  AXIN2       TACCGGAGGATGCTGAAGGC                 CCACTGGCCGATTCTTCCTT

###### Primers used in the qRT-PCR assays for indicated miRNA or lncRNA

  Name             Life Technologies ID   Category                          Species
  ---------------- ---------------------- --------------------------------- --------------
  MIR100HG         Hs03680804_m1          TaqMan ® LncRNA Assay             homo sapiens
  pri-mir-100      Hs03302731_pri         TaqMan ® Pri-miRNA Assay          homo sapiens
  pri-mir-125b-1   Hs03303095_pri         TaqMan ® Pri-miRNA Assay          homo sapiens
  pri-let-7a-2     Hs03302539_pri         TaqMan ® Pri-miRNA Assay          homo sapiens
  miR-100          \# 4427975 000437      TaqMan® MicroRNA Assays           homo sapiens
  miR-125b         \# 4427975 000449      TaqMan® MicroRNA Assays           homo sapiens
  let-7a           \# 4427975 000377      TaqMan® MicroRNA Assays           homo sapiens
  ACTB             Hs01060665_g1          TaqMan ® gene expression Assay    homo sapiens
  U6 snRNA         \# 4427975 001973      TaqMan® microRNA Control Assays   homo sapiens

###### Primers used for Sanger sequencing of *KRAS*, *NRAS*, and *BRAF*

  Locus                                                   Primer Code                   Prime Sequence (5′ to 3′)
  ------------------------------------------------------- ----------------------------- ---------------------------
  *KRAS* Codon G12, G13                                   KRAS-exon2-F                  GTTCTAATATAGTCACATTTTCA
  KRAS-exon2-R                                            TCTATTGTTGGATCATATTCG         
  *KRAS* Codon Q61                                        KRAS-exon3-F                  TCTCCCTTCTCAGGATTC
  KRAS-exon3-R                                            ATTATTTATGGCAAATACACAAAG      
  *KRAS* Codon A146                                       KRAS-exon4-F                  TTCTAGAACAGTAGACACAAAAC
  KRAS-exon4-R                                            GAGAGAAAAACTGATATATTAAATGAC   
  *KRAS* Codon K117                                       KRAS-exon4-2F                 CTTTCCCAGAGAACAAATTAAAAG
  KRAS-exon4-2R                                           TCAATAAAAGGAATTCCATAACTTCT    
  *NRAS* Codon G12, G13                                   NRAS-exon2-F                  CTGATTACTGGTTTCCAACAG
  NRAS-exon2-R                                            CCTCTATGGTGGGATCATATTC        
  *NRAS* Codon Q61                                        NRAS-exon3-F                  CCCCAGGATTCTTACAGAAAA
  NRAS-exon3-R                                            TTGATGGCAAATACACAGAG          
  *BRAF* Codon G465, G468, Y472                           BRAF-exon11-2F                GGGACTCGAGTGATGA
  BRAF-exon11-2R                                          AAAAGTTGTTAAACATATCCTATT      
  *BRAF* Codon D593, F594, L596, L597, T598, V600, K601   BRAF-exon15-2F                ATGAGATCTACTGTTTTCCTTTACT
  BRAF-exon15-2R                                          CCTCAATTCTTACCATCCACA         
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![Characterization of cetuximab-resistant CC (CC-CR) in 3D\
(**a**) Schematic of experimental approach to establish cetuximab (CTX)-resistant cells in 3D. In the presence of CTX (3 μg/ml) in 3D type-1 collagen culture, greater than 95% of CC colonies die. Residual colonies were isolated and iteratively passaged in 2D and 3D in the continued presence of CTX over approximately 4 months. These colonies were designated CC-CR. (**b**) Top: differential interference contrast (DIC) and confocal images of representative CC and CC-CR in 2D and 3D. F-actin was stained with phalloidin (red). Scale bars: 400, 1000, 200, 50 μm, respectively (from left to right). Bottom: left, number of nuclei in the midplane of each colony; right, the morphology of colonies was divided into those with luminal, multi-layered, or solid morphology. n=4 independent experiments, \**P*\<0.05 by Student\'s *t* test. (**c**) CC and CC-CR were cultured in 3D in the presence or absence of CTX (3 μg/ml) and colonies were counted after 18 days. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by Student\'s *t* test. (**d**) CC and CC-CR cells were cultured in 3D for 12 days and treated with CTX (10 μg/ml) for 24 h. Ki-67 (red) and Cleaved Caspase-3 (Cleaved Casp-3, green) staining were imaged by confocal microscopy. Representative of 4 independent experiments. Scale bar, 50 μm. Quantification is shown on the right (n=4). \*\**P*\<0.01 by Student\'s *t* test. (**e**) Immunoblots of 3D cell lysates from CC and CC-CR treated with CTX (10 μg/ml) for indicated time. β-actin served as the loading control. A representative blot from 3 independent experiments is shown. (**f**) Nude mice (n=8) bearing subcutaneous tumors were treated with control saline or CTX at a dose of 1 mg/mouse, intraperitoneal (i.p.) injection, every 3 days. Tumor volumes were measured every 3 days using calipers. \*\**P*\<0.01 by repeated-measures ANOVA test followed by LSD post-hoc test. (**g**) Representative immunohistochemical images of Ki-67 and Cleaved Casp-3 from CC and CC-CR xenografts before and after CTX treatment. Scale bar: 50 μm. Data represent mean ± s.d. in b-d and f. n.s., not significant.](nihms905237f12){#F12}

![Transcriptome profiling of CC and CC-CR in 3D\
(**a**) Left, heatmap of top 50 differentially expressed transcripts in CC-CR versus CC from 3 independent 3D culture experiments. Gene expression values are gene-wise z-transformed and are colored red for high abundance and blue for low abundance, as indicated in the scale bar. Right, miRNA heatmap showing miRNAs altered (\>2-fold and FDR\<0.01) in CC-CR versus CC. (**b**) Genomic organization of lncRNA MIR100HG, host gene of miR-100/let-7a-2/miR-125b-1 cluster, on human chromosome 11 (hsa chr11). (**c**) qRT-PCR showing upregulation of lncRNA MIR100HG, miR-100 and miR-125b in CC-CR compared to CC in 3D. In CC-CR, cells were treated with CTX (CTX+, 3 μg/ml) or normal culture medium (CTX-) for 14 consecutive days in 3D. ACTB or U6 snRNA served as the internal control, respectively. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test. (**d**) Scatter plots of MIR100HG versus miR-100 or miR-125b expression in TCGA CRC data repository. Pearson correlation coefficients (*r*) and *P* values are shown. (**e**) RNA FISH showing high MIR100HG (red) expression in CC-CR mouse tumor xenografts compared to CC xenografts. Concomitantly, high miR-100 (green) and miR-125b (red) signals were observed in CC-CR tumors; the yellow fluorescent signal indicates co-expression of miR-100 and miR-125b. Scale bars, 50 μm. (**f**) qRT-PCR analysis of MIR100HG, miR-100 and miR-125b expression levels among a panel of 30 CRC cell lines ranked by their responsiveness to cetuximab (see Extended Data Table 3). ACTB or U6 snRNA served as the internal control. Fold changes were normalized to CC. n.d., not detected. n=3 independent experiments performed in triplicate. Data represent mean ± s.d. in c and f.](nihms905237f13){#F13}

![Cooperativity of miR-100 and miR-125b in CTX resistance\
(**a, b**) Indicated cells were grown in 3D in normal medium (CTL) or treated with CTX (3 μg/ml) in 3D. The resultant colonies were counted after 18 days. Sponge (Sp). n=3 independent experiments performed in triplicate. \**P*\<0.05, \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with CTL-Sp or miR-CTL. (**c, d**) Left: indicated cells were cultured in 3D for 12 days and CTX (10 μg/ml) was added for 24 h before cells were fixed, stained for Cleaved Casp-3 (cyan) and Ki-67 (magenta). Scale bars, 50 μm. Right: quantification of the morphological changes among indicated cell lines. n=4 independent experiments. (**e, f**) Left: indicated cells were injected subcutaneously into nude mice (n=8). After tumor size reached approximately 100 mm^3^, the mice received CTX treatment (1 mg/mouse, i.p. injection every 3 days). Representative fluorescent images of GFP signals captured from subcutaneous tumors are shown. Middle: growth curve of tumors in nude mice (n=8) injected with cells as indicated. \*\**P*\<0.01 by repeated-measures ANOVA test followed by Dunnett\'s test. Right: tumors (n=8) were isolated on day 28 after treatment and tumor weight was calculated. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test compared with CTL-Sp or miR-CTL. Data represent mean ± s.d. n.s., not significant.](nihms905237f14){#F14}

![miR-100 and miR-125b augment Wnt signaling by repressing multiple Wnt negative regulators\
(**a**) Predicted miR-100 (red) and miR-125b (blue) binding sites in 3′ untranslated regions (3′ UTRs) of human DKK1, DKK3, ZNRF3, RNF43, and APC2. CDS, coding sequence. (**b, c**) Dual luciferase assays of candidates predicted to be regulated by miR-100 or miR-125b. *Renilla* luciferase activity was normalized to firefly activity and presented as relative luciferase activity. n=2 independent experiments. \*\**P*\<0.01 by Student\'s *t* test. (**d**) Immunoblots of indicated proteins in stable miRNA-transduced CC and sponge (Sp)-transduced CC-CR. Representative of 3 independent experiments. (**e**) Immunofluorescence of p-β-catenin (Y489). Scale bars, 50 μm. Right, quantification of 4 independent experiments. \*\**P\<*0.01 by Student\'s *t* test. (**f**) Representative IHC of β-catenin in CC and CC-CR xenografts (n=8). Scale bars: 50 μm (main); 20 μm (inset). Quantification of nuclear β-catenin-positive cells is shown. \*\**P*\<0.01 by Student\'s *t* test. (**g**) qRT-PCR analysis of Wnt target genes in CC and CC-CR cells. n=3 independent experiments performed in triplicate. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. (**h**) qRT-PCR analysis of Wnt target genes in the indicated stable miRNA-transduced CC cells. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test. (**i**) CC-CR were injected subcutaneously into nude mice (n=6). When tumor size reached around 100 mm^3^, mice were treated with control saline, or CTX (1 mg/mouse, i.p. injection every 3 days) and/or ICG-001 (150 mg/kg i.p. injection daily). Representative *in vivo* fluorescent images are shown. (**j**) Growth curve of tumors in nude mice (n=6) treated with different compounds. \*\**P*\<0.01 by repeated-measures ANOVA test followed by LSD post-hoc test. (**k**) Tumors (n=6) were isolated on day 28 after treatment and tumor weight was measured. \*\**P*\<0.01 by one-way ANOVA followed by LSD post-hoc test. Data represent mean ± s.d.](nihms905237f15){#F15}

![GATA6 transcriptionally represses MIR100HG and is targeted by miR-125b in a double-negative feedback loop\
(**a**) Immunoblot of GATA6 in CC and CC-CR cells cultured in 3D. In CC-CR, cells were treated with CTX (CTX+, 3 μg/ml) or normal culture medium (CTX-) for consecutive 14 days in 3D before protein extraction. Representative of 3 independent experiments. (**b**) Immunofluorescence of GATA6 (green) and nuclei (blue). Scale bar, 50 μm. (**c**) Representative IHC of GATA6 in CC and CC-CR xenografts (n=8). (**d**) qRT-PCR analysis of MIR100HG and GATA6 expression at indicated time points following CTX treatment (10 μg/ml) in CC cultured in 3D. n=3 independent experiments. (e) CC cells were transfected with two independent siRNAs against GATA6 or control (siCTL), treated with CTX (10 μg/ml) and subjected to qRT-PCR analysis. n=2 independent experiments performed in triplicate. \*\**P*\<0.01 by Student\'s *t* test. (**f**) Luciferase reporter assays were performed by co-transfection of pGL3-MIR100HG promoter luciferase reporter with increasing concentrations of pcDNA3.1-GATA6 plasmid or empty vector control (CTL), along with a *Renilla* luciferase reporter. Luciferase activity was measured 36 h post-transfection and normalized to *Renilla* values. n=3 independent experiments performed in triplicate. \*\**P*\<0.01 by one-way ANOVA followed by Dunnett\'s test. (**g**) A schematic representation of consecutive deletion and mutation constructs spanning the -2000∼+500 region of MIR100HG promoter. The putative GATA6-binding sites within MIR100HG promoter are shown in black boxes. (**h**) The luciferase vector pGL3 driven by either wild-type, deletion or mutant (MUT) promoter was transfected in CC-CR, and luciferase activity was measured. n=3 independent experiments. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t* test. (**i**) Luciferase reporter analysis of a wild-type (WT) or mutant (MUT) GATA6 3′ UTR activity upon addition of either synthetic miR-125b or a negative control miR-CTL. \*\**P*\<0.01 by Student\'s *t* test. (**j**) Immunoblots of GATA6 in stable miR-125b-transduced CC and 125b-Sp-transduced CC-CR. Representative of 3 independent experiments. (**k**) Box plots showing expression of GATA6 (left) and MIR100HG (middle) by stage from the TCGA CRC data repository. Right panel depicts MIR100HG expression in the lower (\<25%) and the higher (\>75%) quartile of GATA6 expression. \**P*\<0.05, \*\**P*\<0.01 by Mann-Whitney *U* test. n.s., not significant. Data represent mean ± s.d. in d-f, h, and i.](nihms905237f16){#F16}

![Increased MIR100HG and miR-100/125b are found in CRC patient specimens at time of progression on cetuximab\
(**a**) qRT-PCR of miR-100 and miR-125b levels in 10 pairs of matched human CRC specimens pre- and post-cetuximab resistance. Each symbol represents mean value of an individual patient. \**P*\<0.05 by Wilcoxon matched-pairs signed rank test. (**b, c**) Frequency of nuclear β-catenin-positive cells (**b**) and GATA6-positive cells (**c**) in 10 pairs of matched human CRC specimens pre- and post-cetuximab resistance. \**P*\<0.05 by Wilcoxon matched-pairs signed rank test. (**d**) Representative FISH images of MIR100HG, miR-100/125b and corresponding IHC images of β-catenin and GATA6 staining in representative three paired human CRC specimens obtained pre- and post-cetuximab resistance. Scale bars, 50 μm (main); 500 μm (inset).](nihms905237f17){#F17}
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